{"gene":"NOS3","run_date":"2026-06-10T05:19:52","timeline":{"discoveries":[{"year":2010,"finding":"S-glutathionylation of eNOS at two conserved cysteine residues in the reductase domain reversibly decreases NO production and increases superoxide generation, uncoupling the enzyme. This modification is increased in hypertensive vessels and is reversed by thiol-specific reducing agents, restoring endothelium-dependent vasodilation.","method":"In vitro biochemical assay, site-directed mutagenesis of cysteine residues, EPR spectroscopy for superoxide detection, vascular functional studies, and Western blot in hypertensive vessel tissue","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with mutagenesis identifying specific sites, corroborated by functional vascular assays and disease-state tissue analysis in a single rigorous study","pmids":["21179168"],"is_preprint":false},{"year":2007,"finding":"Rho-kinase directly phosphorylates eNOS at Thr495 in vitro, and constitutively active RhoA or Rho-kinase increases this phosphorylation in cells. Thrombin-induced phosphorylation at Thr495 in HUVECs is suppressed by the Rho-kinase inhibitor Y27632, suppressing NO production.","method":"In vitro kinase assay with constitutively active Rho-kinase, overexpression of constitutively active RhoA/Rho-kinase in COS-7 cells, pharmacological inhibition with Y27632 in HUVECs","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay plus cell-based validation with inhibitor, single lab but orthogonal methods","pmids":["17651694"],"is_preprint":false},{"year":2012,"finding":"NO produced by eNOS activates Src kinase, which phosphorylates caveolin-1 at Tyr-14, increasing eNOS/caveolin-1 binding and inhibiting eNOS activity — a negative feedback loop. Phosphomimetic Y14D-Cav-1 increases eNOS/Cav-1 interaction and reduces NO production, whereas phosphodefective Y14F-Cav-1 does not.","method":"FRET biosensor for eNOS/Cav-1 interaction, coimmunoprecipitation, Src FRET biosensor, eNOS siRNA, NO donor studies, phosphomimetic/phosphodefective Cav-1 mutant overexpression","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — multiple orthogonal approaches (FRET, Co-IP, mutagenesis, siRNA) in a single study establishing the feedback mechanism","pmids":["22323292"],"is_preprint":false},{"year":2018,"finding":"Caveolin-1 stabilizes eNOS expression and regulates its activity; loss of Cav-1 reduces eNOS protein but increases per-molecule eNOS phosphorylation and NO production. eNOS activation leads to Cav-1 S-nitrosylation and destabilization of Cav-1 oligomers, promoting caveola-mediated endocytosis of albumin and insulin.","method":"Cav-1 siRNA, adenoviral Cav-1-GFP overexpression, Ca2+ ionophore activation, immunofluorescence, S-nitrosylation assay, caveola-mediated endocytosis measurement, eNOS Ser1177 phosphorylation by Western blot","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal loss- and gain-of-function with multiple endpoints and orthogonal methods in a single study","pmids":["29563255"],"is_preprint":false},{"year":2005,"finding":"PKCalpha isoform specifically stimulates eNOS by increasing phosphorylation at Ser1179 (equivalent to human Ser1177) and NO production in endothelial cells. Inhibition of PKCalpha via siRNA or dominant-negative mutant reduces FGF2-induced Ser1179 phosphorylation and NO production. In vivo PKCalpha transduction increases resting blood flow in an eNOS-dependent manner.","method":"PKCalpha overexpression and siRNA knockdown in primary endothelial cells, dominant-negative mutant, phosphospecific Western blot, in vivo adenoviral gene transfer to rat femoral arteries with blood flow measurement and L-NAME inhibition","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — loss- and gain-of-function in vitro plus in vivo functional validation with NOS inhibitor control","pmids":["16081872"],"is_preprint":false},{"year":2006,"finding":"eNOS undergoes differential translocation depending on the agonist: ACh causes eNOS to translocate preferentially to the trans-Golgi network (associated with vasodilation), whereas PAF causes preferential translocation to the cytosol (associated with hyperpermeability), representing a spatial mechanism for discrimination between vascular responses.","method":"eNOS-GFP stable transfection in ECV-304 cells, lipid raft analysis, immunofluorescence microscopy, endothelial permeability assays","journal":"American journal of physiology. Heart and circulatory physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — live-cell imaging with functional permeability readout, single lab, no mutagenesis or reconstitution","pmids":["16679407"],"is_preprint":false},{"year":2005,"finding":"Hyperhomocysteinemia impairs eNOS activity primarily through PKC activation, which increases phosphorylation of eNOS at Thr495 and decreases eNOS protein expression. A PKC inhibitor (GFX) reverses Hcy-mediated eNOS inactivation and Thr495 phosphorylation in human aortic endothelial cells.","method":"CBS(-/-) mouse model, aortic ring functional assays, intravital microscopy, eNOS activity assay in MAECs and HAECs, Western blot for phospho-eNOS, PKC inhibitor rescue","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic mouse model plus pharmacological rescue, single lab, multiple orthogonal endpoints","pmids":["16210565"],"is_preprint":false},{"year":2006,"finding":"PKCzeta phosphorylates ERK5 at S486, inhibiting ERK5 function and thereby decreasing eNOS protein stability. TNFα stimulates PKCζ to bind ERK5 (shown by Co-IP and mammalian 2-hybrid assay), leading to reduced eNOS protein levels; this is replicated by the ERK5-S486A mutant.","method":"Coimmunoprecipitation, mammalian 2-hybrid assay, in vitro kinase assay, dominant-negative PKCζ, siRNA, phosphomutant ERK5, Western blot for eNOS protein stability","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — binding confirmed by Co-IP and 2-hybrid, phosphorylation site identified by mutagenesis, single lab","pmids":["20538799"],"is_preprint":false},{"year":2020,"finding":"Endogenous NOS3 resides at two distinct subcellular locations—the plasma membrane and the trans-Golgi network (TGN). Using a targeted DNA-based fluorescent probe (NOckout), NOS3 at the plasma membrane was found to be ~10-fold more active than at the Golgi; however, Golgi NOS3 activity is essential for structural integrity of the Golgi.","method":"DNA-based fluorescent probe (NOckout) targeted to plasma membrane or TGN in live cells, quantitative NO mapping, loss-of-function experiments","journal":"Nature chemical biology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — novel subcellular-resolution quantitative activity mapping with functional consequence established, rigorous single-study design","pmids":["32152543"],"is_preprint":false},{"year":2008,"finding":"In tumor cells, the PI3K-AKT pathway activates eNOS (NOS3), which S-nitrosylates endogenous wild-type Ras proteins, activating them; this AKT-eNOS-wild-type Ras axis is required for both tumor initiation and maintenance downstream of oncogenic Ras. Blocking AKT-mediated phosphorylation of eNOS inhibits tumor growth.","method":"Genetic and pharmacological blocking of eNOS phosphorylation in cancer cell lines, mouse tumor models, S-nitrosylation assays for Ras, epistasis analysis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — epistasis established by multiple genetic and biochemical approaches in vitro and in vivo in a single rigorous study","pmids":["18344980"],"is_preprint":false},{"year":2006,"finding":"Fenofibrate activates AMPK in HUVECs and thereby increases eNOS phosphorylation at Ser-1177 and NO production; this effect is not blocked by PKA or PI3K inhibitors, distinguishing AMPK as the relevant kinase in this context.","method":"Western blot for AMPK and ACC phosphorylation, eNOS Ser1177 phosphorylation, NO measurement, pharmacological inhibitors in HUVECs","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — single lab, single method per endpoint, no direct AMPK-eNOS reconstitution","pmids":["16442496"],"is_preprint":false},{"year":2010,"finding":"Tbx5 deletion in endocardial cells results in activation of Nos3 (eNOS), which drives increased apoptosis of endocardial and neighboring myocardial cells, causing atrial septal defects. Compound haploinsufficiency of Tbx5 and Nos3 worsens the cardiac phenotype, establishing genetic epistasis where Nos3 acts downstream of Tbx5 in an endocardial cell-survival pathway.","method":"Conditional Tbx5 knockout in mice, compound Tbx5/Nos3 haploinsufficiency, apoptosis assays, echocardiography, genetic epistasis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic epistasis demonstrated in vivo by compound haploinsufficiency with defined phenotypic readout","pmids":["20974940"],"is_preprint":false},{"year":2001,"finding":"ecNOS-derived NO mediates the acute (4 h) TNF-alpha-induced increase in endothelial permeability in pulmonary microvessel endothelial monolayers, as shown by antisense knockdown of ecNOS preventing the permeability increase; however, the prolonged (24 h) TNF-induced barrier dysfunction is independent of NO.","method":"ecNOS antisense oligonucleotide knockdown, NO measurement, albumin permeability assay, NO donor rescue experiment","journal":"American journal of physiology. Lung cellular and molecular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — antisense knockdown with functional readout plus rescue, single lab","pmids":["11290515"],"is_preprint":false},{"year":2020,"finding":"beta-Arrestin2 forms a complex with GIT1 and eNOS in sinusoidal endothelial cells, directly stimulates eNOS activity and NO production, and this complex is disrupted during liver injury. Overexpression of beta-Arr2 in injured SECs rescues eNOS function; beta-Arr2-mediated GIT1/eNOS complex formation depends on Erk1/2 and Src kinases.","method":"Coimmunoprecipitation, beta-Arr2 knockout mice with bile duct ligation, adenoviral overexpression rescue, eNOS activity assay, pharmacological kinase inhibition","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP, genetic KO with disease phenotype, rescue experiments, multiple orthogonal methods in a single study","pmids":["32404425"],"is_preprint":false},{"year":2019,"finding":"eNOS phosphorylation (as measured by phosphospecific immunoblot) does not necessarily reflect actual NO production. Insulin and VEGF elicit strong eNOS phosphorylation responses but cause no increase in intracellular NO or Ca2+, whereas histamine and ATP promote both phosphorylation and robust NO formation, demonstrating discordance between eNOS phosphorylation and enzyme activation.","method":"Multispectral biosensor imaging of intracellular NO and Ca2+, chemogenetic eNOS activation, phosphospecific immunoblot in cultured endothelial cells","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — multiple orthogonal biosensor methods plus chemogenetics, directly refutes surrogate marker assumption","pmids":["31527268"],"is_preprint":false},{"year":2017,"finding":"Nox4-driven superoxide generation in aging endothelial cells activates PDI chaperone and induces ER stress, which dissociates HSP90 from eNOS and causes eNOS uncoupling (decreased NO, increased superoxide). Nox4 siRNA or chemical inhibition reverses eNOS uncoupling in aged HUVECs.","method":"Serial-passage HUVEC aging model, Nox4 siRNA, ER stress inhibitors, HSP90-eNOS coimmunoprecipitation, NO and superoxide measurement","journal":"Free radical biology & medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — siRNA knockdown plus Co-IP, single lab, no structural or reconstitution data","pmids":["28916474"],"is_preprint":false},{"year":2013,"finding":"Phosphorylation of eNOS at S1176 (mouse equivalent of human S1177) controls insulin sensitivity and metabolism: knockin mice with unphosphorylatable S1176A mutation develop insulin resistance, hyperinsulinemia, and adiposity, while phosphomimetic S1176D mice have decreased insulin levels and resistance to high-fat diet weight gain.","method":"Knockin mouse models (S1176A and S1176D), metabolic phenotyping, glucose/insulin tolerance tests, high-fat diet challenge","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 2 / Moderate — knockin mouse models with phosphomimetic and unphosphorylatable mutations provide clean genetic evidence, single lab","pmids":["23291238"],"is_preprint":false},{"year":2005,"finding":"Laminar shear stress increases eNOS mRNA 3' poly(A) tail length, which prolongs mRNA half-life (from ~6 h to ~18 h) and shifts eNOS mRNA into more translationally active polysome fractions. This nuclear polyadenylation is also induced by hydrogen peroxide and statins.","method":"Poly(A) tail length analysis, actinomycin D chase for mRNA stability, polysome fractionation, nuclear polyadenylation assay in endothelial cells under shear stress","journal":"Circulation research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal post-transcriptional methods, single lab","pmids":["15905462"],"is_preprint":false},{"year":2005,"finding":"NOSIP (NOS-interacting protein) co-immunoprecipitates with eNOS in lung tissue, indicating a direct protein-protein interaction. NOSIP and eNOS co-localize in ciliated airway epithelial cells and vascular/bronchial smooth muscle, suggesting NOSIP contributes to regulation of eNOS activity and availability in airways.","method":"Coimmunoprecipitation from lung tissue, RT-PCR, immunohistochemistry","journal":"The journal of histochemistry and cytochemistry","confidence":"Medium","confidence_rationale":"Tier 3 / Weak — single Co-IP with localization data, no functional activity assay in this study","pmids":["15684328"],"is_preprint":false},{"year":1996,"finding":"In cardiac myocytes, NOS3 mRNA and protein are downregulated by cAMP-elevating agents at the transcriptional level (mRNA half-life unchanged). This downregulation is cell-type specific (not seen in cardiac microvascular endothelial cells) and results in accentuated contractile response to beta-adrenergic stimulation and loss of muscarinic cholinergic response.","method":"In vitro cAMP-elevating drug treatment, in vivo milrinone treatment, Northern/Western blot, mRNA half-life measurement, isolated cardiomyocyte contractility assay","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo and in vitro with transcriptional mechanism and functional contractility readout, single lab","pmids":["8621775"],"is_preprint":false},{"year":2022,"finding":"Elevated endothelial BACE1 cleaves occludin, causing caveolin-1 membrane accumulation; the increased membrane caveolin-1 binds eNOS and attenuates eNOS activity, resulting in endothelial dysfunction. This pathway is demonstrated in endothelial-specific BACE1 transgenic mice and human hypertensive cerebral microvessels.","method":"Mass spectrometry substrate identification, immunostaining, BACE1 transgenic mice, BACE1 inhibitor experiments, Western blot for eNOS-caveolin-1 interaction","journal":"Circulation research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — substrate identified by MS, mechanistic pathway in transgenic mice and inhibitor rescue, single lab","pmids":["35382554"],"is_preprint":false},{"year":2023,"finding":"VEGFR2 phosphosite Y1173 activates PLCγ, which triggers Ca2+/PKC-dependent activation of eNOS. eNOS-derived NO promotes tyrosine nitration and activation of Src, which phosphorylates VE-cadherin at Y685, disintegrating endothelial junctions and causing vascular leakage.","method":"Vegfr2Y1173F/+ knockin mice, Plcg1 endothelial-specific knockout, eNOS activity assay, Src activation measurement, VE-cadherin phosphorylation, vascular permeability assays","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic knockin and endothelial-specific KO in vivo with multiple orthogonal mechanistic endpoints establishing a defined signaling pathway","pmids":["37651195"],"is_preprint":false},{"year":2018,"finding":"OxLDL induces iNOS-dependent S-nitrosylation of eNOS at Cys94 and Cys99 (but not Cys441), which enhances interaction between eNOS and β-catenin, activates β-catenin transcriptional activity, and promotes cell migration and adhesion molecule expression in endothelial cells. Mutation of Cys94/Cys99 partially abolishes these effects.","method":"eNOS Cys mutagenesis, S-nitrosylation assay, coimmunoprecipitation of eNOS/β-catenin, iNOS-specific inhibitor 1400W, β-catenin reporter assay","journal":"Biochimica et biophysica acta. Molecular basis of disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — site-directed mutagenesis plus Co-IP and functional readouts, single lab","pmids":["29471036"],"is_preprint":false},{"year":2022,"finding":"DF-induced endothelial TXNDC5 increases proteasome-mediated degradation of HSF1, reducing HSP90 expression, which accelerates eNOS protein degradation. Endothelium-specific Txndc5 deletion markedly reduces atherosclerosis in ApoE-/- mice. Nanoparticle-delivered CRISPR-Cas9 targeting Txndc5 increases eNOS protein and reduces atherosclerosis in vivo.","method":"Endothelium-specific Txndc5 knockout in ApoE-/- mice, nanoparticle CRISPR delivery, Western blot for HSF1/HSP90/eNOS stability, proteasome inhibition experiments","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic KO plus CRISPR therapeutic proof-of-concept with mechanistic pathway (TXNDC5-HSF1-HSP90-eNOS) established by multiple approaches","pmids":["35061532"],"is_preprint":false},{"year":2021,"finding":"Hepatocyte-specific eNOS is required for normal mitochondrial fatty acid oxidation and mitophagic responses in liver. Genetic deletion or viral knockdown of hepatocyte eNOS exacerbates hepatic steatosis, inflammation, and mitochondrial dysfunction (reduced respiration, increased H2O2), while hepatocyte eNOS overexpression attenuates Western diet-induced NASH.","method":"Hepatocyte-specific eNOS genetic deletion and AAV-mediated knockdown/overexpression in mice, mitochondrial respiration, fatty acid oxidation, mitophagy markers (BNIP3, LC3II), Western diet feeding","journal":"Diabetes","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal loss- and gain-of-function genetic models with mechanistic readouts and human tissue correlation","pmids":["34380696"],"is_preprint":false},{"year":2006,"finding":"In the setting of diabetes (db/db mice), eNOS exists in an uncoupled state producing peroxynitrite rather than NO, and genetic overexpression of eNOS in this context exacerbates hepatic ischemia-reperfusion injury. Repletion with BH4 cofactor (or its precursor sepiapterin) re-couples eNOS and is hepatoprotective, establishing BH4 deficiency as the mechanism of diabetic eNOS uncoupling.","method":"eNOS transgenic and adenoviral overexpression in db/db mice, hepatic I/R injury model, serum ALT measurement, peroxynitrite detection, BH4 and sepiapterin treatment rescue","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — transgenic and gene therapy models with pharmacological rescue establishing BH4-dependent uncoupling mechanism","pmids":["16763164"],"is_preprint":false},{"year":2001,"finding":"PI3-kinase mediates isoproterenol (beta2-adrenergic)- and IGF-1-induced ecNOS activation in rat aortic endothelial cells, as shown by increased citrulline production blocked by Wortmannin. Isoproterenol also enhances eNOS association with the Triton X-100-insoluble (membrane raft) fraction, linking PI3K signaling to eNOS membrane localization.","method":"PI3K activity assay, citrulline production assay, Wortmannin inhibition, Triton X-100 fractionation in rat aortic endothelial cells","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — pharmacological inhibition with activity assay and fractionation, single lab, no genetic confirmation","pmids":["11467844"],"is_preprint":false},{"year":2006,"finding":"Hydroxyurea induces rapid, transient phosphorylation of eNOS at Ser1177 in a PKA-dependent manner (partially via PKB/Akt), increases cAMP, cGMP, and intracellular Ca2+ in HUVECs, leading to increased NO production. This effect is blocked by competitive NOS inhibitors.","method":"Western blot for eNOS Ser1177 phosphorylation, PKA and Akt inhibitors, cAMP/cGMP measurement, intracellular Ca2+ imaging, NO measurement, NOS competitive inhibitors in HUVECs and TrHBMEC","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — pharmacological dissection of pathway with multiple readouts, single lab, no direct kinase reconstitution","pmids":["16527893"],"is_preprint":false},{"year":2007,"finding":"FXR (farnesoid X receptor) activation induces eNOS expression in vascular endothelial cells at the transcriptional level. An imperfect inverted repeat DNA motif (IR2, -628 to -641 in rat eNOS promoter) acts as an FXR-responsive element. FXR ligand treatment increases eNOS mRNA, protein, and nitrite/nitrate production; the effect is blocked by actinomycin D.","method":"Actinomycin D transcription inhibition, eNOS promoter-reporter assay, pharmacological and genetic FXR activation, RT-PCR and Western blot for eNOS, nitrite/nitrate measurement","journal":"Cardiovascular research","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — promoter functional analysis with multiple approaches, single lab","pmids":["18006476"],"is_preprint":false},{"year":2016,"finding":"PGC-1alpha promotes eNOS expression and activity through the orphan nuclear receptor ERRalpha. Endothelial-specific PGC-1alpha deletion sensitizes mice to endothelial dysfunction, while overexpression protects against it; protection is abolished by L-NAME or eNOS deletion, placing eNOS downstream of the PGC-1alpha/ERRalpha axis.","method":"Endothelial-specific PGC-1alpha knockout and transgenic mice, angiotensin-II hypertension model, L-NAME and eNOS KO epistasis, vascular reactivity assays","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis in vivo with multiple complementary mouse models, single lab","pmids":["27910955"],"is_preprint":false},{"year":2023,"finding":"KLF2 increases eNOS phosphorylation at Ser1177 and eNOS dimerization, and activates the PI3K-Akt pathway and HSP90 to promote eNOS activity. Adenovirus-mediated endothelium-specific KLF2 overexpression enhances endothelium-dependent relaxation and flow-mediated dilation in diabetic mice.","method":"Adenoviral KLF2 overexpression in mouse aortic endothelium, RNA-sequencing, Western blot for eNOS phosphorylation and dimerization, Akt/HSP90 pathway analysis, vascular function assays in db/db mice","journal":"Diabetes","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo gene delivery with mechanistic pathway analysis, single lab","pmids":["37347764"],"is_preprint":false},{"year":2015,"finding":"Circulating NOS3 from blood cells (distinct from endothelial NOS3) ameliorates maladaptive left ventricular remodeling following reperfused myocardial infarction, reducing scar size and collagen deposition. Bone marrow chimeras devoid of blood-cell NOS3 show worsened LV remodeling compared to chimeras with both endothelial and blood-cell NOS3.","method":"Bone marrow transplantation chimera approach (NOS3-/- BM into WT mice), 60-min coronary occlusion/reperfusion model, serial echocardiography, pressure catheter hemodynamics, post-mortem histology","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — genetic chimera model with functional cardiac readout, single lab","pmids":["25875863"],"is_preprint":false},{"year":2017,"finding":"Functionally distinct platelet subpopulations exist: approximately 20% of platelets lack eNOS and consequently fail to produce NO and have downregulated sGC-PKG signaling. eNOS-negative platelets primarily initiate adhesion to collagen and form larger aggregates, while eNOS-positive platelets limit aggregate size via NO generation.","method":"Flow cytometry to separate eNOS-positive and eNOS-negative platelet subpopulations, flow chamber adhesion assays, aggregation experiments, MMP-2 secretion measurement, integrin αIIbβ3 activation assay","journal":"Cardiovascular research","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — functional subpopulation separation with multiple readouts, single lab","pmids":["29016749"],"is_preprint":false},{"year":1994,"finding":"Hypoxia reduces eNOS mRNA in human endothelial cells by both decreasing transcription and reducing message stability (40-60% reduction). This leads to decreased NO production, as functional co-culture experiments show hypoxic endothelial cells stimulate significantly less cGMP production by smooth muscle cells.","method":"Northern blot, nuclear run-on transcription assay, mRNA stability assay, endothelial-smooth muscle co-culture cGMP measurement under normoxia and hypoxia","journal":"The American journal of physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — dual transcriptional and post-transcriptional mechanisms with functional co-culture validation, single lab","pmids":["7526714"],"is_preprint":false},{"year":2018,"finding":"TRPC5 channels activated by ATP-induced IP3 signaling stimulate eNOS/NOS activation and NO-cGMP-PKG signaling in neonatal rat cardiomyocytes. This TRPC5-eNOS axis negatively regulates hypertrophic TRPC3/6-calcineurin/NFAT signaling; pharmacological NOS inhibition potentiates ATP-induced NFAT activity and protein synthesis.","method":"NOS inhibitors, TRPC5 and TRPC6 selective pharmacological inhibition, NFAT reporter assay, NO measurement, PKG activity assay, protein synthesis measurement in NRCMs","journal":"Frontiers in pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — pharmacological pathway dissection with multiple readouts, single lab, no direct TRPC5-eNOS interaction assay","pmids":["29872396"],"is_preprint":false},{"year":2015,"finding":"eNOS deficiency in mice causes podocyte cellular hypertrophy, mitochondrial abnormalities (increased number/decreased size), mitochondrial DNA mutations (d-17), reduced renal ATP and mitochondrial respiration. Conditioned medium lacking NO induces mitochondrial fragmentation in cultured podocytes, which is rescued by NO donor.","method":"eNOS knockout mice, ultrastructural analysis, mitochondrial respiration assay in primary podocytes, ATP measurement, NO donor rescue, endothelial conditioned medium experiments","journal":"Free radical biology & medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with ultrastructural, biochemical and cell culture rescue evidence, single lab","pmids":["26119782"],"is_preprint":false},{"year":2004,"finding":"eNOS (NOS3) protects prostate cancer cells from TRAIL-induced apoptosis. Stable eNOS-expressing PC-3 clones are resistant to TRAIL-induced apoptosis, and NOS inhibition sensitizes LNCaP (high endogenous eNOS/Akt) cells to TRAIL. This protection is mediated downstream of Akt.","method":"Stable eNOS-overexpressing cell clone generation, NOS inhibitor treatment, apoptosis assays, Akt activity measurement in multiple prostate cancer cell lines","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — stable overexpression and pharmacological inhibition with defined apoptosis readout, single lab","pmids":["15172122"],"is_preprint":false},{"year":1998,"finding":"Adventitial expression of recombinant eNOS gene in fibroblasts (via adenoviral vector) restores NO production and bradykinin-induced relaxation in basilar arteries without endothelium, demonstrating that eNOS functional activity in adventitial fibroblasts is sufficient to regulate vascular tone through cGMP production. This effect is blocked by the NOS inhibitor L-NAME.","method":"Ex vivo adenoviral eNOS gene transfer to canine basilar arteries, endothelium-removal experiments, isometric tension recording, cGMP radioimmunoassay, electron microscopy for protein localization","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reconstitution via gene transfer in denuded vessels with functional and biochemical validation, single lab","pmids":["9714129"],"is_preprint":false}],"current_model":"NOS3/eNOS is a Ca2+/calmodulin-dependent oxygenase that produces NO from L-arginine in the endothelium; its activity is precisely tuned by multisite phosphorylation (activating at Ser1177, inhibitory at Thr495 via Rho-kinase or PKC), reversible post-translational modifications (S-glutathionylation and S-nitrosylation at defined cysteines that uncouple or inhibit the enzyme), protein-protein interactions (caveolin-1 tonically inhibits, HSP90/β-arrestin2/GIT1 stimulate), and subcellular compartmentalization between the plasma membrane (primary activity site, ~10-fold more active) and trans-Golgi network (required for Golgi structural integrity); BH4 cofactor availability determines coupling state, and upstream kinases including Akt, PKCalpha, AMPK, and ERK5 (regulated by PKCζ) converge on eNOS phosphorylation to control NO output, while eNOS-derived NO itself drives a negative feedback through Src-mediated caveolin-1 phosphorylation."},"narrative":{"mechanistic_narrative":"NOS3 (eNOS) is a Ca2+/calmodulin-regulated enzyme that generates nitric oxide (NO) to control vascular tone, endothelial barrier function, and broader cardiometabolic homeostasis, with its output tuned by multisite phosphorylation, redox-based cysteine modifications, protein partners, and subcellular compartmentalization [PMID:32152543, PMID:31527268]. Enzyme activity is bidirectionally set by phosphorylation: activating phosphorylation at Ser1177 is driven by PKCalpha, AMPK, PKA/Akt, and KLF2-linked PI3K-Akt/HSP90 signaling, whereas inhibitory Thr495 phosphorylation by Rho-kinase or PKC suppresses NO production [PMID:16081872, PMID:16442496, PMID:17651694, PMID:16210565, PMID:37347764]. Phosphorylation status alone, however, does not predict NO output, establishing activation as a multi-input process rather than a single switch [PMID:31527268]. Catalytic coupling depends on redox state and cofactor availability: S-glutathionylation of reductase-domain cysteines and BH4 deficiency uncouple the enzyme to produce superoxide or peroxynitrite, while iNOS-dependent S-nitrosylation at Cys94/Cys99 redirects eNOS into a beta-catenin transcriptional complex [PMID:21179168, PMID:16763164, PMID:29471036]. eNOS is held inactive by caveolin-1 and is reciprocally regulated by its own product through an NO-Src-caveolin-1 Tyr14 negative-feedback loop, while beta-arrestin2/GIT1 complexes and HSP90 stimulate activity; HSP90 association and eNOS protein stability are themselves controlled by chaperone and degradation pathways (Nox4/ER stress, TXNDC5-HSF1-HSP90) [PMID:22323292, PMID:29563255, PMID:32404425, PMID:28916474, PMID:35061532]. Spatially, endogenous eNOS partitions between the plasma membrane, where it is ~10-fold more active, and the trans-Golgi network, where its activity is required for Golgi structural integrity [PMID:32152543]. Beyond the vasculature, eNOS-derived NO S-nitrosylates and activates wild-type Ras to support tumor maintenance, governs Ser1177-dependent insulin sensitivity, and is required for hepatocyte mitochondrial fatty acid oxidation [PMID:18344980, PMID:23291238, PMID:34380696].","teleology":[{"year":1994,"claim":"Established that eNOS NO output is gated at the level of message abundance, showing oxygen tension controls endothelial NO production through transcription and mRNA stability.","evidence":"Nuclear run-on, mRNA stability assays, and endothelial-smooth muscle co-culture cGMP measurement under hypoxia","pmids":["7526714"],"confidence":"Medium","gaps":["Promoter elements and trans-factors not identified","Does not address post-translational regulation"]},{"year":1996,"claim":"Demonstrated cell-type-specific transcriptional downregulation of NOS3 by cAMP in cardiomyocytes, linking eNOS abundance to beta-adrenergic and muscarinic contractile responses.","evidence":"cAMP-elevating drugs in vitro and milrinone in vivo with cardiomyocyte contractility assays","pmids":["8621775"],"confidence":"Medium","gaps":["Transcription factor mediating cAMP effect not identified","Restricted to cardiomyocyte context"]},{"year":1998,"claim":"Showed eNOS catalytic function is sufficient to control vascular tone independent of its native endothelial location, by reconstituting NO-dependent relaxation in denuded vessels via adventitial fibroblast expression.","evidence":"Ex vivo adenoviral eNOS gene transfer to endothelium-removed canine basilar arteries with tension recording and cGMP RIA","pmids":["9714129"],"confidence":"Medium","gaps":["Did not test physiological regulation of ectopic enzyme","cGMP-independent effects not addressed"]},{"year":2001,"claim":"Connected receptor signaling to eNOS by showing PI3K mediates beta2-adrenergic and IGF-1 activation of eNOS and its partitioning into membrane rafts.","evidence":"PI3K activity and citrulline assays with Wortmannin inhibition and Triton X-100 fractionation in rat aortic endothelial cells","pmids":["11467844"],"confidence":"Medium","gaps":["Pharmacological inhibition only, no genetic confirmation","Direct kinase target on eNOS not defined here"]},{"year":2001,"claim":"Distinguished the temporal role of eNOS-derived NO in barrier control, showing NO mediates only the acute phase of TNF-induced endothelial permeability.","evidence":"ecNOS antisense knockdown with albumin permeability assay and NO donor rescue in pulmonary microvessel monolayers","pmids":["11290515"],"confidence":"Medium","gaps":["Antisense specificity limited","Mechanism of NO-independent late-phase dysfunction unresolved"]},{"year":2005,"claim":"Resolved isoform-specific activating kinase input by showing PKCalpha drives Ser1177 phosphorylation and NO production with in vivo blood-flow consequences.","evidence":"PKCalpha overexpression/siRNA, dominant-negative mutant, and in vivo adenoviral transfer with L-NAME control","pmids":["16081872"],"confidence":"High","gaps":["Whether PKCalpha acts directly or via intermediate kinase not fully resolved"]},{"year":2005,"claim":"Linked hyperhomocysteinemia to eNOS dysfunction via PKC-driven inhibitory Thr495 phosphorylation and reduced expression.","evidence":"CBS-/- mice, aortic ring assays, and PKC inhibitor rescue in human aortic endothelial cells","pmids":["16210565"],"confidence":"Medium","gaps":["Specific PKC isoform not identified","Mechanism of expression decrease not defined"]},{"year":2005,"claim":"Identified a post-transcriptional mechanism by which laminar shear stress stabilizes eNOS mRNA through poly(A) tail lengthening and enhanced translation.","evidence":"Poly(A) tail analysis, actinomycin D chase, and polysome fractionation in sheared endothelial cells","pmids":["15905462"],"confidence":"Medium","gaps":["Polyadenylation machinery responsible not identified"]},{"year":2005,"claim":"Identified NOSIP as a direct eNOS-interacting protein co-localizing in airway and vascular tissues.","evidence":"Co-immunoprecipitation from lung tissue with immunohistochemistry","pmids":["15684328"],"confidence":"Medium","gaps":["Single Co-IP without functional activity assay","Effect on eNOS activity not directly demonstrated"]},{"year":2006,"claim":"Defined AMPK as a distinct Ser1177-activating kinase under fenofibrate stimulation, independent of PKA/PI3K.","evidence":"Phospho-Western blots and pharmacological inhibitor dissection in HUVECs","pmids":["16442496"],"confidence":"Medium","gaps":["No direct AMPK-eNOS reconstitution","Single method per endpoint"]},{"year":2006,"claim":"Mapped a PKCzeta-ERK5 axis controlling eNOS protein stability, showing TNFalpha lowers eNOS via PKCzeta phosphorylation of ERK5 at S486.","evidence":"Co-IP, mammalian 2-hybrid, in vitro kinase assay, and ERK5 phosphomutant analysis","pmids":["20538799"],"confidence":"Medium","gaps":["Mechanism by which ERK5 stabilizes eNOS not defined","Single lab"]},{"year":2006,"claim":"Established BH4 cofactor deficiency as the mechanism of diabetic eNOS uncoupling, where eNOS produces peroxynitrite and BH4/sepiapterin repletion re-couples the enzyme.","evidence":"eNOS transgenic/adenoviral overexpression in db/db mice with hepatic I/R injury and BH4 rescue","pmids":["16763164"],"confidence":"High","gaps":["Quantitative BH4 thresholds for coupling not defined"]},{"year":2006,"claim":"Showed eNOS subcellular destination is agonist-selective, with ACh routing to the trans-Golgi (vasodilation) and PAF to cytosol (hyperpermeability).","evidence":"eNOS-GFP imaging, lipid raft analysis, and permeability assays in ECV-304 cells","pmids":["16679407"],"confidence":"Medium","gaps":["No mutagenesis defining the trafficking signal","Endogenous protein not examined"]},{"year":2006,"claim":"Connected hydroxyurea pharmacology to eNOS, showing PKA-dependent (partly Akt) Ser1177 phosphorylation and NO production.","evidence":"Phospho-Western, kinase inhibitors, cyclic nucleotide and Ca2+ measurement in HUVECs","pmids":["16527893"],"confidence":"Medium","gaps":["No direct kinase reconstitution"]},{"year":2007,"claim":"Identified Rho-kinase as the direct kinase for inhibitory Thr495 phosphorylation, linking RhoA signaling to NO suppression.","evidence":"In vitro kinase assay with constitutively active Rho-kinase plus Y27632 inhibition in HUVECs","pmids":["17651694"],"confidence":"High","gaps":["Physiological agonists engaging this axis only partly defined"]},{"year":2007,"claim":"Identified FXR as a transcriptional activator of eNOS via a defined promoter response element.","evidence":"Promoter-reporter assays, actinomycin D, and FXR ligand treatment in endothelial cells","pmids":["18006476"],"confidence":"Medium","gaps":["Element characterized in rat promoter; human conservation not shown"]},{"year":2008,"claim":"Revealed a non-vascular oncogenic function, showing AKT-activated eNOS S-nitrosylates and activates wild-type Ras to drive tumor initiation and maintenance.","evidence":"Genetic/pharmacological eNOS phospho-blockade, Ras S-nitrosylation assays, and mouse tumor models with epistasis","pmids":["18344980"],"confidence":"High","gaps":["Cysteine target on Ras not mapped here","Tissue specificity of the axis not fully defined"]},{"year":2010,"claim":"Defined reversible S-glutathionylation of reductase-domain cysteines as a redox switch that uncouples eNOS toward superoxide and is elevated in hypertension.","evidence":"In vitro reconstitution with cysteine mutagenesis, EPR, and hypertensive vessel analysis","pmids":["21179168"],"confidence":"High","gaps":["Enzymes mediating de/re-glutathionylation in vivo not identified"]},{"year":2010,"claim":"Placed Nos3 in a developmental cell-survival pathway, showing it acts downstream of Tbx5 to drive endocardial apoptosis and atrial septal defects.","evidence":"Conditional Tbx5 knockout and compound Tbx5/Nos3 haploinsufficiency with apoptosis assays and echocardiography","pmids":["20974940"],"confidence":"High","gaps":["Mechanism by which Tbx5 represses Nos3 not defined"]},{"year":2012,"claim":"Established a product-driven negative feedback loop in which eNOS-derived NO activates Src to phosphorylate caveolin-1 Tyr14, enhancing inhibitory eNOS/Cav-1 binding.","evidence":"FRET biosensors, Co-IP, eNOS siRNA, and Cav-1 phosphomimetic/phosphodefective mutants","pmids":["22323292"],"confidence":"High","gaps":["Quantitative contribution to steady-state NO not defined"]},{"year":2013,"claim":"Demonstrated that Ser1177 phosphorylation is a physiological setpoint for systemic metabolism using phosphomutant knockin mice.","evidence":"S1176A and S1176D knockin mice with metabolic phenotyping and high-fat diet challenge","pmids":["23291238"],"confidence":"High","gaps":["Tissue source of the metabolic NO effect not isolated"]},{"year":2015,"claim":"Identified a blood-cell pool of NOS3 distinct from endothelium that limits maladaptive cardiac remodeling after myocardial infarction.","evidence":"Bone marrow chimera transplantation with reperfused MI model and serial echocardiography","pmids":["25875863"],"confidence":"Medium","gaps":["Blood cell type responsible not pinpointed","Single lab"]},{"year":2015,"claim":"Linked endothelial eNOS-derived NO to podocyte mitochondrial integrity, showing eNOS loss causes mitochondrial abnormalities rescuable by NO donor.","evidence":"eNOS knockout mice with podocyte ultrastructure, respiration assays, and conditioned-medium NO rescue","pmids":["26119782"],"confidence":"Medium","gaps":["Molecular target of NO in podocyte mitochondria not defined"]},{"year":2016,"claim":"Placed eNOS downstream of the PGC-1alpha/ERRalpha axis as the effector protecting against endothelial dysfunction.","evidence":"Endothelial PGC-1alpha knockout/transgenic mice with L-NAME and eNOS-KO epistasis","pmids":["27910955"],"confidence":"Medium","gaps":["Direct ERRalpha binding to eNOS promoter not shown here"]},{"year":2017,"claim":"Connected oxidative aging to eNOS uncoupling via Nox4-driven ER stress that dissociates HSP90 from eNOS.","evidence":"Serial-passage HUVEC aging, Nox4 siRNA, ER stress inhibitors, and HSP90-eNOS Co-IP","pmids":["28916474"],"confidence":"Medium","gaps":["No structural or reconstitution data on HSP90-eNOS dissociation"]},{"year":2017,"claim":"Revealed platelet heterogeneity in which an eNOS-negative subpopulation drives adhesion while eNOS-positive platelets limit aggregate size.","evidence":"Flow-cytometric subpopulation separation with adhesion and aggregation assays","pmids":["29016749"],"confidence":"Medium","gaps":["Basis of eNOS expression dichotomy not defined","Single lab"]},{"year":2018,"claim":"Clarified caveolin-1 as both a stabilizer and inhibitor of eNOS, with eNOS activity in turn destabilizing Cav-1 oligomers to drive caveolar endocytosis.","evidence":"Reciprocal Cav-1 siRNA/overexpression, S-nitrosylation assay, and endocytosis measurement","pmids":["29563255"],"confidence":"High","gaps":["Stoichiometry balancing stabilization versus inhibition not resolved"]},{"year":2018,"claim":"Defined site-specific S-nitrosylation at Cys94/Cys99 that redirects eNOS into a beta-catenin transcriptional complex promoting endothelial activation.","evidence":"Cys mutagenesis, S-nitrosylation assay, eNOS/beta-catenin Co-IP, and reporter assays","pmids":["29471036"],"confidence":"Medium","gaps":["Source iNOS context required; endogenous relevance partly defined","Single lab"]},{"year":2018,"claim":"Established TRPC5 as an upstream activator of eNOS that restrains hypertrophic TRPC3/6-calcineurin/NFAT signaling in cardiomyocytes.","evidence":"TRPC5/6 inhibitors, NFAT reporter, PKG activity, and protein synthesis assays in NRCMs","pmids":["29872396"],"confidence":"Medium","gaps":["No direct TRPC5-eNOS interaction assay"]},{"year":2020,"claim":"Mapped endogenous eNOS to two pools with distinct activity, showing plasma-membrane eNOS is ~10-fold more active while Golgi eNOS activity maintains Golgi structure.","evidence":"Subcellular-targeted DNA fluorescent NO probe (NOckout) with quantitative live-cell mapping","pmids":["32152543"],"confidence":"High","gaps":["Mechanism coupling Golgi NO to structural maintenance not defined"]},{"year":2020,"claim":"Identified a beta-arrestin2/GIT1/eNOS stimulatory complex required for sinusoidal endothelial NO production that is lost in liver injury.","evidence":"Reciprocal Co-IP, beta-Arr2 knockout mice with bile duct ligation, and rescue with kinase inhibition","pmids":["32404425"],"confidence":"High","gaps":["Structural organization of the tripartite complex not resolved"]},{"year":2019,"claim":"Refuted phosphorylation as a reliable surrogate for NO output, showing insulin/VEGF cause eNOS phosphorylation without NO while histamine/ATP cause both.","evidence":"Multispectral NO/Ca2+ biosensor imaging with chemogenetic activation and phospho-immunoblot","pmids":["31527268"],"confidence":"High","gaps":["Additional activation steps distinguishing the two responses not fully defined"]},{"year":2021,"claim":"Demonstrated a hepatocyte-intrinsic eNOS requirement for mitochondrial fatty acid oxidation and mitophagy, protective against diet-induced NASH.","evidence":"Hepatocyte-specific eNOS deletion and AAV knockdown/overexpression with mitochondrial respiration and mitophagy readouts","pmids":["34380696"],"confidence":"High","gaps":["Direct mitochondrial NO targets in hepatocytes not identified"]},{"year":2022,"claim":"Defined a BACE1-occludin-caveolin-1 pathway in which BACE1 elevation increases membrane caveolin-1 to sequester and inhibit eNOS in hypertensive microvessels.","evidence":"MS substrate identification, BACE1 transgenic mice, inhibitor experiments, and human hypertensive microvessels","pmids":["35382554"],"confidence":"Medium","gaps":["Link between occludin cleavage and Cav-1 accumulation mechanistically incomplete"]},{"year":2022,"claim":"Established a TXNDC5-HSF1-HSP90 degradation axis controlling eNOS protein levels and validated CRISPR targeting to restore eNOS and reduce atherosclerosis.","evidence":"Endothelium-specific Txndc5 knockout in ApoE-/- mice, nanoparticle CRISPR delivery, and proteasome/stability assays","pmids":["35061532"],"confidence":"High","gaps":["Whether HSP90 reduction alone fully accounts for eNOS loss not resolved"]},{"year":2023,"claim":"Defined a VEGFR2-Y1173/PLCgamma-Ca2+/PKC-eNOS pathway in which NO nitrates and activates Src to disrupt VE-cadherin junctions and cause vascular leakage.","evidence":"Vegfr2 Y1173F knockin and endothelial Plcg1 knockout mice with Src/VE-cadherin and permeability readouts","pmids":["37651195"],"confidence":"High","gaps":["Relationship to the eNOS phosphorylation switches not integrated"]},{"year":2023,"claim":"Identified KLF2 as a transcriptional/signaling node enhancing eNOS Ser1177 phosphorylation, dimerization, and PI3K-Akt/HSP90 activity to improve diabetic vascular function.","evidence":"Adenoviral endothelial KLF2 overexpression with RNA-seq, phospho/dimerization Western, and vascular function in db/db mice","pmids":["37347764"],"confidence":"Medium","gaps":["Direct versus indirect effect of KLF2 on eNOS dimerization not separated"]},{"year":null,"claim":"How the converging phosphorylation, redox, cofactor, partner, and compartmentalization inputs are integrated quantitatively to determine actual NO output in vivo remains unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No unified model relating phospho-state, coupling, and localization to measured NO","Structural basis of partner-driven activation/inhibition undefined","Tissue-specific eNOS pools incompletely mapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016491","term_label":"oxidoreductase activity","supporting_discovery_ids":[0,25,8]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[9,22]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[34,2]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[8,26,5]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[8,5]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[5]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[4,1,21]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[16,24,25]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[23,20,6]},{"term_id":"R-HSA-109582","term_label":"Hemostasis","supporting_discovery_ids":[32]}],"complexes":["beta-arrestin2/GIT1/eNOS complex","eNOS/caveolin-1 complex","HSP90/eNOS complex"],"partners":["CAV1","HSP90AA1","ARRB2","GIT1","SRC","NOSIP","CTNNB1","ROCK1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P60323","full_name":"Nanos homolog 3","aliases":[],"length_aa":173,"mass_kda":18.8,"function":"Plays a role in the maintenance of the undifferentiated state of germ cells regulating the spermatogonia cell cycle and inducing a prolonged transit in G1 phase. Affects cell proliferation probably by repressing translation of specific mRNAs. Maintains the germ cell lineage by suppressing both Bax-dependent and -independent apoptotic pathways. Essential in the early stage embryo to protect the migrating primordial germ cells (PGCs) from apoptosis","subcellular_location":"Nucleus; Cytoplasm; Cytoplasm, Stress granule; Cytoplasm, P-body","url":"https://www.uniprot.org/uniprotkb/P60323/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/NOS3","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/NOS3","total_profiled":1310},"omim":[{"mim_id":"621469","title":"MOYAMOYA DISEASE 8; MYMY8","url":"https://www.omim.org/entry/621469"},{"mim_id":"620533","title":"LONG INTERGENIC NONCODING RNA 520; LINC00520","url":"https://www.omim.org/entry/620533"},{"mim_id":"618556","title":"ENERGY HOMEOSTASIS-ASSOCIATED PROTEIN; ENHO","url":"https://www.omim.org/entry/618556"},{"mim_id":"617888","title":"ZINC FINGER PROTEIN 580; ZNF580","url":"https://www.omim.org/entry/617888"},{"mim_id":"617334","title":"ZDHHC PALMITOYLTRANSFERASE 23; ZDHHC23","url":"https://www.omim.org/entry/617334"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":59.4}],"url":"https://www.proteinatlas.org/search/NOS3"},"hgnc":{"alias_symbol":["ECNOS","eNOS"],"prev_symbol":[]},"alphafold":{"accession":"P60323","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P60323","model_url":"https://alphafold.ebi.ac.uk/files/AF-P60323-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P60323-F1-predicted_aligned_error_v6.png","plddt_mean":70.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=NOS3","jax_strain_url":"https://www.jax.org/strain/search?query=NOS3"},"sequence":{"accession":"P60323","fasta_url":"https://rest.uniprot.org/uniprotkb/P60323.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P60323/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P60323"}},"corpus_meta":[{"pmid":"26499181","id":"PMC_26499181","title":"Vascular nitric oxide: Beyond eNOS.","date":"2015","source":"Journal of pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/26499181","citation_count":576,"is_preprint":false},{"pmid":"9530221","id":"PMC_9530221","title":"VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells.","date":"1998","source":"The American journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/9530221","citation_count":513,"is_preprint":false},{"pmid":"21179168","id":"PMC_21179168","title":"S-glutathionylation uncouples eNOS and regulates its cellular and vascular function.","date":"2010","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/21179168","citation_count":468,"is_preprint":false},{"pmid":"10690325","id":"PMC_10690325","title":"Signal transduction of eNOS activation.","date":"1999","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/10690325","citation_count":353,"is_preprint":false},{"pmid":"20012875","id":"PMC_20012875","title":"Molecular mechanisms underlying the activation of eNOS.","date":"2009","source":"Pflugers Archiv : European journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/20012875","citation_count":330,"is_preprint":false},{"pmid":"17466957","id":"PMC_17466957","title":"Life history of eNOS: partners and pathways.","date":"2007","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/17466957","citation_count":309,"is_preprint":false},{"pmid":"19767531","id":"PMC_19767531","title":"eNOS uncoupling and endothelial dysfunction in aged vessels.","date":"2009","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/19767531","citation_count":303,"is_preprint":false},{"pmid":"7526714","id":"PMC_7526714","title":"Hypoxia inhibits expression of eNOS via transcriptional and posttranscriptional mechanisms.","date":"1994","source":"The American journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/7526714","citation_count":274,"is_preprint":false},{"pmid":"18344980","id":"PMC_18344980","title":"Tumour maintenance is mediated by eNOS.","date":"2008","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/18344980","citation_count":259,"is_preprint":false},{"pmid":"21198553","id":"PMC_21198553","title":"Therapeutic effect of enhancing endothelial nitric oxide synthase (eNOS) expression and preventing eNOS uncoupling.","date":"2011","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/21198553","citation_count":236,"is_preprint":false},{"pmid":"15111011","id":"PMC_15111011","title":"Targeting eNOS for stroke protection.","date":"2004","source":"Trends in neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/15111011","citation_count":218,"is_preprint":false},{"pmid":"35072089","id":"PMC_35072089","title":"Endothelial Nitric Oxide Synthase (eNOS) and the Cardiovascular System: in Physiology and in Disease States.","date":"2022","source":"American journal of biomedical science & research","url":"https://pubmed.ncbi.nlm.nih.gov/35072089","citation_count":218,"is_preprint":false},{"pmid":"30621010","id":"PMC_30621010","title":"New Therapeutic Implications of Endothelial Nitric Oxide Synthase (eNOS) Function/Dysfunction in Cardiovascular Disease.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30621010","citation_count":213,"is_preprint":false},{"pmid":"15162796","id":"PMC_15162796","title":"Role of eNOS in neovascularization: NO for endothelial progenitor cells.","date":"2004","source":"Trends in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15162796","citation_count":210,"is_preprint":false},{"pmid":"24180389","id":"PMC_24180389","title":"Regulation of eNOS enzyme activity by posttranslational modification.","date":"2014","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/24180389","citation_count":145,"is_preprint":false},{"pmid":"9867209","id":"PMC_9867209","title":"Increased expression of endothelial cell nitric oxide synthase (ecNOS) in afferent and glomerular endothelial cells is involved in glomerular hyperfiltration of diabetic nephropathy.","date":"1998","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/9867209","citation_count":145,"is_preprint":false},{"pmid":"20363286","id":"PMC_20363286","title":"eNOS phosphorylation in health and disease.","date":"2010","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/20363286","citation_count":143,"is_preprint":false},{"pmid":"27184745","id":"PMC_27184745","title":"The eNOS signalosome and its link to endothelial dysfunction.","date":"2016","source":"Pflugers Archiv : European journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/27184745","citation_count":134,"is_preprint":false},{"pmid":"12060581","id":"PMC_12060581","title":"Relationships between caveolae and eNOS: everything in proximity and the proximity of everything.","date":"2002","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12060581","citation_count":126,"is_preprint":false},{"pmid":"16210565","id":"PMC_16210565","title":"Hyperhomocystinemia impairs endothelial function and eNOS activity via PKC activation.","date":"2005","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16210565","citation_count":126,"is_preprint":false},{"pmid":"31998130","id":"PMC_31998130","title":"Doxorubicin Induces Endotheliotoxicity and Mitochondrial Dysfunction via ROS/eNOS/NO Pathway.","date":"2020","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31998130","citation_count":123,"is_preprint":false},{"pmid":"26428312","id":"PMC_26428312","title":"Endothelial nitric oxide synthase: From biochemistry and gene structure to clinical implications of NOS3 polymorphisms.","date":"2015","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/26428312","citation_count":117,"is_preprint":false},{"pmid":"22323292","id":"PMC_22323292","title":"Nitric oxide-dependent Src activation and resultant caveolin-1 phosphorylation promote eNOS/caveolin-1 binding and eNOS inhibition.","date":"2012","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/22323292","citation_count":108,"is_preprint":false},{"pmid":"18006476","id":"PMC_18006476","title":"FXR-mediated regulation of eNOS expression in vascular endothelial cells.","date":"2007","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/18006476","citation_count":100,"is_preprint":false},{"pmid":"29563255","id":"PMC_29563255","title":"Reciprocal regulation of eNOS and caveolin-1 functions in endothelial cells.","date":"2018","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/29563255","citation_count":99,"is_preprint":false},{"pmid":"17651694","id":"PMC_17651694","title":"Rho-kinase phosphorylates eNOS at threonine 495 in endothelial cells.","date":"2007","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/17651694","citation_count":88,"is_preprint":false},{"pmid":"16168996","id":"PMC_16168996","title":"Susceptible and protective eNOS haplotypes in hypertensive black and white subjects.","date":"2005","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/16168996","citation_count":86,"is_preprint":false},{"pmid":"30937466","id":"PMC_30937466","title":"Roles of eNOS in atherosclerosis treatment.","date":"2019","source":"Inflammation research : official journal of the European Histamine Research Society ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/30937466","citation_count":85,"is_preprint":false},{"pmid":"16081872","id":"PMC_16081872","title":"PKCalpha activates eNOS and increases arterial blood flow in vivo.","date":"2005","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/16081872","citation_count":82,"is_preprint":false},{"pmid":"21968328","id":"PMC_21968328","title":"Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins?","date":"2011","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/21968328","citation_count":82,"is_preprint":false},{"pmid":"16446491","id":"PMC_16446491","title":"eNOS function and dysfunction in the penis.","date":"2006","source":"Experimental biology and medicine (Maywood, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/16446491","citation_count":81,"is_preprint":false},{"pmid":"22411313","id":"PMC_22411313","title":"Regulation of eNOS in caveolae.","date":"2012","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/22411313","citation_count":75,"is_preprint":false},{"pmid":"16442496","id":"PMC_16442496","title":"Fenofibrate activates AMPK and increases eNOS phosphorylation in HUVEC.","date":"2006","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/16442496","citation_count":75,"is_preprint":false},{"pmid":"16763164","id":"PMC_16763164","title":"eNOS gene therapy exacerbates hepatic ischemia-reperfusion injury in diabetes: a role for eNOS uncoupling.","date":"2006","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/16763164","citation_count":71,"is_preprint":false},{"pmid":"10514107","id":"PMC_10514107","title":"Association between Alzheimer's disease and the NOS3 gene.","date":"1999","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/10514107","citation_count":71,"is_preprint":false},{"pmid":"17762636","id":"PMC_17762636","title":"Three endothelial nitric oxide (NOS3) gene polymorphisms in hypertensive and normotensive individuals: meta-analysis of 53 studies reveals evidence of publication bias.","date":"2007","source":"Journal of hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/17762636","citation_count":69,"is_preprint":false},{"pmid":"16527893","id":"PMC_16527893","title":"Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16527893","citation_count":69,"is_preprint":false},{"pmid":"10070092","id":"PMC_10070092","title":"Flow regulation of ecNOS and Cu/Zn SOD mRNA expression in porcine coronary arterioles.","date":"1999","source":"The American journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/10070092","citation_count":65,"is_preprint":false},{"pmid":"10781649","id":"PMC_10781649","title":"Methylene tetrahydrofolate reductase (MTHFR) and nitric oxide synthase (ecNOS) genes and risks of peripheral arterial disease and coronary heart disease: Edinburgh Artery Study.","date":"2000","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/10781649","citation_count":65,"is_preprint":false},{"pmid":"9435309","id":"PMC_9435309","title":"Verotoxin and ricin have novel effects on preproendothelin-1 expression but fail to modify nitric oxide synthase (ecNOS) expression and NO production in vascular endothelium.","date":"1998","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/9435309","citation_count":64,"is_preprint":false},{"pmid":"35382554","id":"PMC_35382554","title":"Endothelial BACE1 Impairs Cerebral Small Vessels via Tight Junctions and eNOS.","date":"2022","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/35382554","citation_count":63,"is_preprint":false},{"pmid":"16679407","id":"PMC_16679407","title":"Functional significance of differential eNOS translocation.","date":"2006","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/16679407","citation_count":62,"is_preprint":false},{"pmid":"20538799","id":"PMC_20538799","title":"PKCzeta decreases eNOS protein stability via inhibitory phosphorylation of ERK5.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20538799","citation_count":60,"is_preprint":false},{"pmid":"20974940","id":"PMC_20974940","title":"An endocardial pathway involving Tbx5, Gata4, and Nos3 required for atrial septum formation.","date":"2010","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/20974940","citation_count":60,"is_preprint":false},{"pmid":"18925469","id":"PMC_18925469","title":"HB-EGF stimulates eNOS expression and nitric oxide production and promotes eNOS dependent angiogenesis.","date":"2008","source":"Growth factors (Chur, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/18925469","citation_count":60,"is_preprint":false},{"pmid":"20069064","id":"PMC_20069064","title":"Association of eNOS and HSP70 gene polymorphisms with glaucoma in Pakistani cohorts.","date":"2010","source":"Molecular vision","url":"https://pubmed.ncbi.nlm.nih.gov/20069064","citation_count":59,"is_preprint":false},{"pmid":"17584103","id":"PMC_17584103","title":"Understanding eNOS for pharmacological modulation of endothelial function: a translational view.","date":"2007","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/17584103","citation_count":57,"is_preprint":false},{"pmid":"12701818","id":"PMC_12701818","title":"Association of ecNOS gene polymorphisms with end stage renal diseases.","date":"2003","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12701818","citation_count":57,"is_preprint":false},{"pmid":"32152543","id":"PMC_32152543","title":"A DNA-based fluorescent probe maps NOS3 activity with subcellular spatial resolution.","date":"2020","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/32152543","citation_count":56,"is_preprint":false},{"pmid":"10338373","id":"PMC_10338373","title":"Expression and functional analysis of endothelial nitric oxide synthase (eNOS) in human placenta.","date":"1999","source":"Molecular human reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/10338373","citation_count":54,"is_preprint":false},{"pmid":"11222793","id":"PMC_11222793","title":"Association of a 27-bp repeat polymorphism in ecNOS gene with ischemic stroke in Chinese patients.","date":"2001","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/11222793","citation_count":53,"is_preprint":false},{"pmid":"24180386","id":"PMC_24180386","title":"Pharmacological prevention of eNOS uncoupling.","date":"2014","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/24180386","citation_count":52,"is_preprint":false},{"pmid":"29016749","id":"PMC_29016749","title":"Differential eNOS-signalling by platelet subpopulations regulates adhesion and aggregation.","date":"2017","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/29016749","citation_count":52,"is_preprint":false},{"pmid":"28916474","id":"PMC_28916474","title":"Nox4 regulates the eNOS uncoupling process in aging endothelial cells.","date":"2017","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28916474","citation_count":52,"is_preprint":false},{"pmid":"31527268","id":"PMC_31527268","title":"Discordance between eNOS phosphorylation and activation revealed by multispectral imaging and chemogenetic methods.","date":"2019","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/31527268","citation_count":51,"is_preprint":false},{"pmid":"11748066","id":"PMC_11748066","title":"Decreased expression of myocardial eNOS and caveolin in dogs with hypertrophic cardiomyopathy.","date":"2002","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11748066","citation_count":50,"is_preprint":false},{"pmid":"9714129","id":"PMC_9714129","title":"Adventitial expression of recombinant eNOS gene restores NO production in arteries without endothelium.","date":"1998","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9714129","citation_count":48,"is_preprint":false},{"pmid":"22198555","id":"PMC_22198555","title":"Current therapeutic strategies to mitigate the eNOS dysfunction in ischaemic stroke.","date":"2011","source":"Cellular and molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/22198555","citation_count":47,"is_preprint":false},{"pmid":"15905462","id":"PMC_15905462","title":"Laminar shear stress and 3' polyadenylation of eNOS mRNA.","date":"2005","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/15905462","citation_count":46,"is_preprint":false},{"pmid":"8621775","id":"PMC_8621775","title":"Nitric oxide synthase (NOS3) and contractile responsiveness to adrenergic and cholinergic agonists in the heart. Regulation of NOS3 transcription in vitro and in vivo by cyclic adenosine monophosphate in rat cardiac myocytes.","date":"1996","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/8621775","citation_count":46,"is_preprint":false},{"pmid":"27910955","id":"PMC_27910955","title":"PGC-1α dictates endothelial function through regulation of eNOS expression.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27910955","citation_count":45,"is_preprint":false},{"pmid":"34403364","id":"PMC_34403364","title":"Roxadustat prevents Ang II hypertension by targeting angiotensin receptors and eNOS.","date":"2021","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/34403364","citation_count":44,"is_preprint":false},{"pmid":"18638569","id":"PMC_18638569","title":"S1P and eNOS regulation.","date":"2008","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/18638569","citation_count":42,"is_preprint":false},{"pmid":"14510773","id":"PMC_14510773","title":"Trafficking and activation of eNOS in epithelial cells.","date":"2003","source":"Acta physiologica Scandinavica","url":"https://pubmed.ncbi.nlm.nih.gov/14510773","citation_count":40,"is_preprint":false},{"pmid":"23291238","id":"PMC_23291238","title":"eNOS phosphorylation on serine 1176 affects insulin sensitivity and adiposity.","date":"2013","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/23291238","citation_count":40,"is_preprint":false},{"pmid":"37651195","id":"PMC_37651195","title":"Endothelial VEGFR2-PLCγ signaling regulates vascular permeability and antitumor immunity through eNOS/Src.","date":"2023","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/37651195","citation_count":39,"is_preprint":false},{"pmid":"11007586","id":"PMC_11007586","title":"Hindlimb unweighting alters endothelium-dependent vasodilation and ecNOS expression in soleus arterioles.","date":"2000","source":"Journal of applied physiology (Bethesda, Md. : 1985)","url":"https://pubmed.ncbi.nlm.nih.gov/11007586","citation_count":39,"is_preprint":false},{"pmid":"28672425","id":"PMC_28672425","title":"Effects of resveratrol on eNOS in the endothelium and the perivascular adipose tissue.","date":"2017","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28672425","citation_count":37,"is_preprint":false},{"pmid":"11467844","id":"PMC_11467844","title":"Role of PI3-kinase in isoproterenol and IGF-1 induced ecNOS activity.","date":"2001","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/11467844","citation_count":37,"is_preprint":false},{"pmid":"27228562","id":"PMC_27228562","title":"eNOS Activity in CAV1 Knockout Mouse Eyes.","date":"2016","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/27228562","citation_count":35,"is_preprint":false},{"pmid":"15172122","id":"PMC_15172122","title":"eNOS protects prostate cancer cells from TRAIL-induced apoptosis.","date":"2004","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/15172122","citation_count":35,"is_preprint":false},{"pmid":"31130510","id":"PMC_31130510","title":"Myricetin ameliorated ischemia/reperfusion-induced brain endothelial permeability by improvement of eNOS uncoupling and activation eNOS/NO.","date":"2019","source":"Journal of pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31130510","citation_count":34,"is_preprint":false},{"pmid":"30134790","id":"PMC_30134790","title":"Stachydrine protects eNOS uncoupling and ameliorates endothelial dysfunction induced by homocysteine.","date":"2018","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/30134790","citation_count":34,"is_preprint":false},{"pmid":"37347764","id":"PMC_37347764","title":"Induction of KLF2 by Exercise Activates eNOS to Improve Vasodilatation in Diabetic Mice.","date":"2023","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/37347764","citation_count":31,"is_preprint":false},{"pmid":"11290515","id":"PMC_11290515","title":"Role of ecNOS-derived NO in mediating TNF-induced endothelial barrier dysfunction.","date":"2001","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11290515","citation_count":31,"is_preprint":false},{"pmid":"11522715","id":"PMC_11522715","title":"Relations between ACE gene and ecNOS gene polymorphisms and resistive index in type 2 diabetic patients with nephropathy.","date":"2001","source":"Diabetes care","url":"https://pubmed.ncbi.nlm.nih.gov/11522715","citation_count":30,"is_preprint":false},{"pmid":"31329047","id":"PMC_31329047","title":"Activation of the STAT1 Pathway Accelerates Periodontitis in Nos3 Mice.","date":"2019","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/31329047","citation_count":30,"is_preprint":false},{"pmid":"18655103","id":"PMC_18655103","title":"Gastroschisis: a gene-environment model involving the VEGF-NOS3 pathway.","date":"2008","source":"American journal of medical genetics. Part C, Seminars in medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18655103","citation_count":28,"is_preprint":false},{"pmid":"11926202","id":"PMC_11926202","title":"Hypertension after renal transplantation and polymorphism of genes involved in essential hypertension: ACE, AGT, AT1 R and ecNOS.","date":"2002","source":"Clinical nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/11926202","citation_count":27,"is_preprint":false},{"pmid":"35061532","id":"PMC_35061532","title":"Targeting mechanosensitive endothelial TXNDC5 to stabilize eNOS and reduce atherosclerosis in vivo.","date":"2022","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/35061532","citation_count":27,"is_preprint":false},{"pmid":"11327094","id":"PMC_11327094","title":"Altered mRNA expression of ecNOS and iNOS in myometrium and placenta from women with preeclampsia.","date":"2001","source":"Archives of gynecology and obstetrics","url":"https://pubmed.ncbi.nlm.nih.gov/11327094","citation_count":26,"is_preprint":false},{"pmid":"11408389","id":"PMC_11408389","title":"Expression and distribution of NOS1 and NOS3 in the myocardium of angiotensin II-infused rats.","date":"2001","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/11408389","citation_count":26,"is_preprint":false},{"pmid":"32404425","id":"PMC_32404425","title":"β-Arrestin2 is a critical component of the GPCR-eNOS signalosome.","date":"2020","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/32404425","citation_count":26,"is_preprint":false},{"pmid":"27696692","id":"PMC_27696692","title":"Gene-Gene Interactions Among PRKCA, NOS3 and BDKRB2 Polymorphisms Affect the Antihypertensive Effects of Enalapril.","date":"2016","source":"Basic & clinical pharmacology & toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/27696692","citation_count":25,"is_preprint":false},{"pmid":"35869262","id":"PMC_35869262","title":"mTOR contributes to endothelium-dependent vasorelaxation by promoting eNOS expression and preventing eNOS uncoupling.","date":"2022","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/35869262","citation_count":25,"is_preprint":false},{"pmid":"27451094","id":"PMC_27451094","title":"Transcriptional and Posttranslational Regulation of eNOS in the Endothelium.","date":"2016","source":"Advances in pharmacology (San Diego, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/27451094","citation_count":25,"is_preprint":false},{"pmid":"32428234","id":"PMC_32428234","title":"ABCA1 Regulates IOP by Modulating Cav1/eNOS/NO Signaling Pathway.","date":"2020","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/32428234","citation_count":25,"is_preprint":false},{"pmid":"11903359","id":"PMC_11903359","title":"Association of a polymorphism of the ecNOS gene with myocardial infarction in a subgroup of Turkish MI patients.","date":"2002","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11903359","citation_count":25,"is_preprint":false},{"pmid":"20049477","id":"PMC_20049477","title":"A meta-analysis of three polymorphisms in the endothelial nitric oxide synthase gene (NOS3) and their effect on the risk of diabetic nephropathy.","date":"2010","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20049477","citation_count":25,"is_preprint":false},{"pmid":"15951350","id":"PMC_15951350","title":"PGE1 analog alprostadil induces VEGF and eNOS expression in endothelial cells.","date":"2005","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/15951350","citation_count":25,"is_preprint":false},{"pmid":"33747912","id":"PMC_33747912","title":"Pan-Cancer Analysis of NOS3 Identifies Its Expression and Clinical Relevance in Gastric Cancer.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33747912","citation_count":24,"is_preprint":false},{"pmid":"25875863","id":"PMC_25875863","title":"Circulating NOS3 modulates left ventricular remodeling following reperfused myocardial infarction.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25875863","citation_count":24,"is_preprint":false},{"pmid":"29872396","id":"PMC_29872396","title":"TRPC5-eNOS Axis Negatively Regulates ATP-Induced Cardiomyocyte Hypertrophy.","date":"2018","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29872396","citation_count":24,"is_preprint":false},{"pmid":"26119782","id":"PMC_26119782","title":"ENOS deficiency causes podocyte injury with mitochondrial abnormality.","date":"2015","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26119782","citation_count":24,"is_preprint":false},{"pmid":"15684328","id":"PMC_15684328","title":"NOSIP and its interacting protein, eNOS, in the rat trachea and lung.","date":"2005","source":"The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society","url":"https://pubmed.ncbi.nlm.nih.gov/15684328","citation_count":23,"is_preprint":false},{"pmid":"12124201","id":"PMC_12124201","title":"ecNOS gene polymorphism is associated with endothelium-dependent vasodilation in Type 2 diabetes.","date":"2002","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12124201","citation_count":23,"is_preprint":false},{"pmid":"29471036","id":"PMC_29471036","title":"eNOS S-nitrosylation mediated OxLDL-induced endothelial dysfunction via increasing the interaction of eNOS with β‑catenin.","date":"2018","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/29471036","citation_count":23,"is_preprint":false},{"pmid":"12126764","id":"PMC_12126764","title":"Beraprost sodium, prostacyclin analogue, attenuates glomerular hyperfiltration and glomerular macrophage infiltration by modulating ecNOS expression in diabetic rats.","date":"2002","source":"Diabetes research and clinical practice","url":"https://pubmed.ncbi.nlm.nih.gov/12126764","citation_count":22,"is_preprint":false},{"pmid":"34380696","id":"PMC_34380696","title":"Critical Role for Hepatocyte-Specific eNOS in NAFLD and NASH.","date":"2021","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/34380696","citation_count":22,"is_preprint":false},{"pmid":"27339197","id":"PMC_27339197","title":"Relationship between endothelial nitric oxide synthase (eNOS) and natural history of intracranial aneurysms: meta-analysis.","date":"2016","source":"Neurosurgical review","url":"https://pubmed.ncbi.nlm.nih.gov/27339197","citation_count":22,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51597,"output_tokens":9779,"usd":0.150738,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":20247,"output_tokens":8762,"usd":0.160142,"stage2_stop_reason":"end_turn"},"total_usd":0.31088,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2010,\n      \"finding\": \"S-glutathionylation of eNOS at two conserved cysteine residues in the reductase domain reversibly decreases NO production and increases superoxide generation, uncoupling the enzyme. This modification is increased in hypertensive vessels and is reversed by thiol-specific reducing agents, restoring endothelium-dependent vasodilation.\",\n      \"method\": \"In vitro biochemical assay, site-directed mutagenesis of cysteine residues, EPR spectroscopy for superoxide detection, vascular functional studies, and Western blot in hypertensive vessel tissue\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with mutagenesis identifying specific sites, corroborated by functional vascular assays and disease-state tissue analysis in a single rigorous study\",\n      \"pmids\": [\"21179168\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Rho-kinase directly phosphorylates eNOS at Thr495 in vitro, and constitutively active RhoA or Rho-kinase increases this phosphorylation in cells. Thrombin-induced phosphorylation at Thr495 in HUVECs is suppressed by the Rho-kinase inhibitor Y27632, suppressing NO production.\",\n      \"method\": \"In vitro kinase assay with constitutively active Rho-kinase, overexpression of constitutively active RhoA/Rho-kinase in COS-7 cells, pharmacological inhibition with Y27632 in HUVECs\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay plus cell-based validation with inhibitor, single lab but orthogonal methods\",\n      \"pmids\": [\"17651694\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"NO produced by eNOS activates Src kinase, which phosphorylates caveolin-1 at Tyr-14, increasing eNOS/caveolin-1 binding and inhibiting eNOS activity — a negative feedback loop. Phosphomimetic Y14D-Cav-1 increases eNOS/Cav-1 interaction and reduces NO production, whereas phosphodefective Y14F-Cav-1 does not.\",\n      \"method\": \"FRET biosensor for eNOS/Cav-1 interaction, coimmunoprecipitation, Src FRET biosensor, eNOS siRNA, NO donor studies, phosphomimetic/phosphodefective Cav-1 mutant overexpression\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — multiple orthogonal approaches (FRET, Co-IP, mutagenesis, siRNA) in a single study establishing the feedback mechanism\",\n      \"pmids\": [\"22323292\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Caveolin-1 stabilizes eNOS expression and regulates its activity; loss of Cav-1 reduces eNOS protein but increases per-molecule eNOS phosphorylation and NO production. eNOS activation leads to Cav-1 S-nitrosylation and destabilization of Cav-1 oligomers, promoting caveola-mediated endocytosis of albumin and insulin.\",\n      \"method\": \"Cav-1 siRNA, adenoviral Cav-1-GFP overexpression, Ca2+ ionophore activation, immunofluorescence, S-nitrosylation assay, caveola-mediated endocytosis measurement, eNOS Ser1177 phosphorylation by Western blot\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal loss- and gain-of-function with multiple endpoints and orthogonal methods in a single study\",\n      \"pmids\": [\"29563255\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"PKCalpha isoform specifically stimulates eNOS by increasing phosphorylation at Ser1179 (equivalent to human Ser1177) and NO production in endothelial cells. Inhibition of PKCalpha via siRNA or dominant-negative mutant reduces FGF2-induced Ser1179 phosphorylation and NO production. In vivo PKCalpha transduction increases resting blood flow in an eNOS-dependent manner.\",\n      \"method\": \"PKCalpha overexpression and siRNA knockdown in primary endothelial cells, dominant-negative mutant, phosphospecific Western blot, in vivo adenoviral gene transfer to rat femoral arteries with blood flow measurement and L-NAME inhibition\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss- and gain-of-function in vitro plus in vivo functional validation with NOS inhibitor control\",\n      \"pmids\": [\"16081872\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"eNOS undergoes differential translocation depending on the agonist: ACh causes eNOS to translocate preferentially to the trans-Golgi network (associated with vasodilation), whereas PAF causes preferential translocation to the cytosol (associated with hyperpermeability), representing a spatial mechanism for discrimination between vascular responses.\",\n      \"method\": \"eNOS-GFP stable transfection in ECV-304 cells, lipid raft analysis, immunofluorescence microscopy, endothelial permeability assays\",\n      \"journal\": \"American journal of physiology. Heart and circulatory physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — live-cell imaging with functional permeability readout, single lab, no mutagenesis or reconstitution\",\n      \"pmids\": [\"16679407\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Hyperhomocysteinemia impairs eNOS activity primarily through PKC activation, which increases phosphorylation of eNOS at Thr495 and decreases eNOS protein expression. A PKC inhibitor (GFX) reverses Hcy-mediated eNOS inactivation and Thr495 phosphorylation in human aortic endothelial cells.\",\n      \"method\": \"CBS(-/-) mouse model, aortic ring functional assays, intravital microscopy, eNOS activity assay in MAECs and HAECs, Western blot for phospho-eNOS, PKC inhibitor rescue\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic mouse model plus pharmacological rescue, single lab, multiple orthogonal endpoints\",\n      \"pmids\": [\"16210565\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"PKCzeta phosphorylates ERK5 at S486, inhibiting ERK5 function and thereby decreasing eNOS protein stability. TNFα stimulates PKCζ to bind ERK5 (shown by Co-IP and mammalian 2-hybrid assay), leading to reduced eNOS protein levels; this is replicated by the ERK5-S486A mutant.\",\n      \"method\": \"Coimmunoprecipitation, mammalian 2-hybrid assay, in vitro kinase assay, dominant-negative PKCζ, siRNA, phosphomutant ERK5, Western blot for eNOS protein stability\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — binding confirmed by Co-IP and 2-hybrid, phosphorylation site identified by mutagenesis, single lab\",\n      \"pmids\": [\"20538799\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Endogenous NOS3 resides at two distinct subcellular locations—the plasma membrane and the trans-Golgi network (TGN). Using a targeted DNA-based fluorescent probe (NOckout), NOS3 at the plasma membrane was found to be ~10-fold more active than at the Golgi; however, Golgi NOS3 activity is essential for structural integrity of the Golgi.\",\n      \"method\": \"DNA-based fluorescent probe (NOckout) targeted to plasma membrane or TGN in live cells, quantitative NO mapping, loss-of-function experiments\",\n      \"journal\": \"Nature chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — novel subcellular-resolution quantitative activity mapping with functional consequence established, rigorous single-study design\",\n      \"pmids\": [\"32152543\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"In tumor cells, the PI3K-AKT pathway activates eNOS (NOS3), which S-nitrosylates endogenous wild-type Ras proteins, activating them; this AKT-eNOS-wild-type Ras axis is required for both tumor initiation and maintenance downstream of oncogenic Ras. Blocking AKT-mediated phosphorylation of eNOS inhibits tumor growth.\",\n      \"method\": \"Genetic and pharmacological blocking of eNOS phosphorylation in cancer cell lines, mouse tumor models, S-nitrosylation assays for Ras, epistasis analysis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — epistasis established by multiple genetic and biochemical approaches in vitro and in vivo in a single rigorous study\",\n      \"pmids\": [\"18344980\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Fenofibrate activates AMPK in HUVECs and thereby increases eNOS phosphorylation at Ser-1177 and NO production; this effect is not blocked by PKA or PI3K inhibitors, distinguishing AMPK as the relevant kinase in this context.\",\n      \"method\": \"Western blot for AMPK and ACC phosphorylation, eNOS Ser1177 phosphorylation, NO measurement, pharmacological inhibitors in HUVECs\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — single lab, single method per endpoint, no direct AMPK-eNOS reconstitution\",\n      \"pmids\": [\"16442496\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Tbx5 deletion in endocardial cells results in activation of Nos3 (eNOS), which drives increased apoptosis of endocardial and neighboring myocardial cells, causing atrial septal defects. Compound haploinsufficiency of Tbx5 and Nos3 worsens the cardiac phenotype, establishing genetic epistasis where Nos3 acts downstream of Tbx5 in an endocardial cell-survival pathway.\",\n      \"method\": \"Conditional Tbx5 knockout in mice, compound Tbx5/Nos3 haploinsufficiency, apoptosis assays, echocardiography, genetic epistasis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis demonstrated in vivo by compound haploinsufficiency with defined phenotypic readout\",\n      \"pmids\": [\"20974940\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"ecNOS-derived NO mediates the acute (4 h) TNF-alpha-induced increase in endothelial permeability in pulmonary microvessel endothelial monolayers, as shown by antisense knockdown of ecNOS preventing the permeability increase; however, the prolonged (24 h) TNF-induced barrier dysfunction is independent of NO.\",\n      \"method\": \"ecNOS antisense oligonucleotide knockdown, NO measurement, albumin permeability assay, NO donor rescue experiment\",\n      \"journal\": \"American journal of physiology. Lung cellular and molecular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — antisense knockdown with functional readout plus rescue, single lab\",\n      \"pmids\": [\"11290515\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"beta-Arrestin2 forms a complex with GIT1 and eNOS in sinusoidal endothelial cells, directly stimulates eNOS activity and NO production, and this complex is disrupted during liver injury. Overexpression of beta-Arr2 in injured SECs rescues eNOS function; beta-Arr2-mediated GIT1/eNOS complex formation depends on Erk1/2 and Src kinases.\",\n      \"method\": \"Coimmunoprecipitation, beta-Arr2 knockout mice with bile duct ligation, adenoviral overexpression rescue, eNOS activity assay, pharmacological kinase inhibition\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP, genetic KO with disease phenotype, rescue experiments, multiple orthogonal methods in a single study\",\n      \"pmids\": [\"32404425\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"eNOS phosphorylation (as measured by phosphospecific immunoblot) does not necessarily reflect actual NO production. Insulin and VEGF elicit strong eNOS phosphorylation responses but cause no increase in intracellular NO or Ca2+, whereas histamine and ATP promote both phosphorylation and robust NO formation, demonstrating discordance between eNOS phosphorylation and enzyme activation.\",\n      \"method\": \"Multispectral biosensor imaging of intracellular NO and Ca2+, chemogenetic eNOS activation, phosphospecific immunoblot in cultured endothelial cells\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — multiple orthogonal biosensor methods plus chemogenetics, directly refutes surrogate marker assumption\",\n      \"pmids\": [\"31527268\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Nox4-driven superoxide generation in aging endothelial cells activates PDI chaperone and induces ER stress, which dissociates HSP90 from eNOS and causes eNOS uncoupling (decreased NO, increased superoxide). Nox4 siRNA or chemical inhibition reverses eNOS uncoupling in aged HUVECs.\",\n      \"method\": \"Serial-passage HUVEC aging model, Nox4 siRNA, ER stress inhibitors, HSP90-eNOS coimmunoprecipitation, NO and superoxide measurement\",\n      \"journal\": \"Free radical biology & medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — siRNA knockdown plus Co-IP, single lab, no structural or reconstitution data\",\n      \"pmids\": [\"28916474\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Phosphorylation of eNOS at S1176 (mouse equivalent of human S1177) controls insulin sensitivity and metabolism: knockin mice with unphosphorylatable S1176A mutation develop insulin resistance, hyperinsulinemia, and adiposity, while phosphomimetic S1176D mice have decreased insulin levels and resistance to high-fat diet weight gain.\",\n      \"method\": \"Knockin mouse models (S1176A and S1176D), metabolic phenotyping, glucose/insulin tolerance tests, high-fat diet challenge\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — knockin mouse models with phosphomimetic and unphosphorylatable mutations provide clean genetic evidence, single lab\",\n      \"pmids\": [\"23291238\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Laminar shear stress increases eNOS mRNA 3' poly(A) tail length, which prolongs mRNA half-life (from ~6 h to ~18 h) and shifts eNOS mRNA into more translationally active polysome fractions. This nuclear polyadenylation is also induced by hydrogen peroxide and statins.\",\n      \"method\": \"Poly(A) tail length analysis, actinomycin D chase for mRNA stability, polysome fractionation, nuclear polyadenylation assay in endothelial cells under shear stress\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal post-transcriptional methods, single lab\",\n      \"pmids\": [\"15905462\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"NOSIP (NOS-interacting protein) co-immunoprecipitates with eNOS in lung tissue, indicating a direct protein-protein interaction. NOSIP and eNOS co-localize in ciliated airway epithelial cells and vascular/bronchial smooth muscle, suggesting NOSIP contributes to regulation of eNOS activity and availability in airways.\",\n      \"method\": \"Coimmunoprecipitation from lung tissue, RT-PCR, immunohistochemistry\",\n      \"journal\": \"The journal of histochemistry and cytochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single Co-IP with localization data, no functional activity assay in this study\",\n      \"pmids\": [\"15684328\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"In cardiac myocytes, NOS3 mRNA and protein are downregulated by cAMP-elevating agents at the transcriptional level (mRNA half-life unchanged). This downregulation is cell-type specific (not seen in cardiac microvascular endothelial cells) and results in accentuated contractile response to beta-adrenergic stimulation and loss of muscarinic cholinergic response.\",\n      \"method\": \"In vitro cAMP-elevating drug treatment, in vivo milrinone treatment, Northern/Western blot, mRNA half-life measurement, isolated cardiomyocyte contractility assay\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo and in vitro with transcriptional mechanism and functional contractility readout, single lab\",\n      \"pmids\": [\"8621775\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Elevated endothelial BACE1 cleaves occludin, causing caveolin-1 membrane accumulation; the increased membrane caveolin-1 binds eNOS and attenuates eNOS activity, resulting in endothelial dysfunction. This pathway is demonstrated in endothelial-specific BACE1 transgenic mice and human hypertensive cerebral microvessels.\",\n      \"method\": \"Mass spectrometry substrate identification, immunostaining, BACE1 transgenic mice, BACE1 inhibitor experiments, Western blot for eNOS-caveolin-1 interaction\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — substrate identified by MS, mechanistic pathway in transgenic mice and inhibitor rescue, single lab\",\n      \"pmids\": [\"35382554\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"VEGFR2 phosphosite Y1173 activates PLCγ, which triggers Ca2+/PKC-dependent activation of eNOS. eNOS-derived NO promotes tyrosine nitration and activation of Src, which phosphorylates VE-cadherin at Y685, disintegrating endothelial junctions and causing vascular leakage.\",\n      \"method\": \"Vegfr2Y1173F/+ knockin mice, Plcg1 endothelial-specific knockout, eNOS activity assay, Src activation measurement, VE-cadherin phosphorylation, vascular permeability assays\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockin and endothelial-specific KO in vivo with multiple orthogonal mechanistic endpoints establishing a defined signaling pathway\",\n      \"pmids\": [\"37651195\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"OxLDL induces iNOS-dependent S-nitrosylation of eNOS at Cys94 and Cys99 (but not Cys441), which enhances interaction between eNOS and β-catenin, activates β-catenin transcriptional activity, and promotes cell migration and adhesion molecule expression in endothelial cells. Mutation of Cys94/Cys99 partially abolishes these effects.\",\n      \"method\": \"eNOS Cys mutagenesis, S-nitrosylation assay, coimmunoprecipitation of eNOS/β-catenin, iNOS-specific inhibitor 1400W, β-catenin reporter assay\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular basis of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — site-directed mutagenesis plus Co-IP and functional readouts, single lab\",\n      \"pmids\": [\"29471036\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"DF-induced endothelial TXNDC5 increases proteasome-mediated degradation of HSF1, reducing HSP90 expression, which accelerates eNOS protein degradation. Endothelium-specific Txndc5 deletion markedly reduces atherosclerosis in ApoE-/- mice. Nanoparticle-delivered CRISPR-Cas9 targeting Txndc5 increases eNOS protein and reduces atherosclerosis in vivo.\",\n      \"method\": \"Endothelium-specific Txndc5 knockout in ApoE-/- mice, nanoparticle CRISPR delivery, Western blot for HSF1/HSP90/eNOS stability, proteasome inhibition experiments\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO plus CRISPR therapeutic proof-of-concept with mechanistic pathway (TXNDC5-HSF1-HSP90-eNOS) established by multiple approaches\",\n      \"pmids\": [\"35061532\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Hepatocyte-specific eNOS is required for normal mitochondrial fatty acid oxidation and mitophagic responses in liver. Genetic deletion or viral knockdown of hepatocyte eNOS exacerbates hepatic steatosis, inflammation, and mitochondrial dysfunction (reduced respiration, increased H2O2), while hepatocyte eNOS overexpression attenuates Western diet-induced NASH.\",\n      \"method\": \"Hepatocyte-specific eNOS genetic deletion and AAV-mediated knockdown/overexpression in mice, mitochondrial respiration, fatty acid oxidation, mitophagy markers (BNIP3, LC3II), Western diet feeding\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal loss- and gain-of-function genetic models with mechanistic readouts and human tissue correlation\",\n      \"pmids\": [\"34380696\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"In the setting of diabetes (db/db mice), eNOS exists in an uncoupled state producing peroxynitrite rather than NO, and genetic overexpression of eNOS in this context exacerbates hepatic ischemia-reperfusion injury. Repletion with BH4 cofactor (or its precursor sepiapterin) re-couples eNOS and is hepatoprotective, establishing BH4 deficiency as the mechanism of diabetic eNOS uncoupling.\",\n      \"method\": \"eNOS transgenic and adenoviral overexpression in db/db mice, hepatic I/R injury model, serum ALT measurement, peroxynitrite detection, BH4 and sepiapterin treatment rescue\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transgenic and gene therapy models with pharmacological rescue establishing BH4-dependent uncoupling mechanism\",\n      \"pmids\": [\"16763164\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"PI3-kinase mediates isoproterenol (beta2-adrenergic)- and IGF-1-induced ecNOS activation in rat aortic endothelial cells, as shown by increased citrulline production blocked by Wortmannin. Isoproterenol also enhances eNOS association with the Triton X-100-insoluble (membrane raft) fraction, linking PI3K signaling to eNOS membrane localization.\",\n      \"method\": \"PI3K activity assay, citrulline production assay, Wortmannin inhibition, Triton X-100 fractionation in rat aortic endothelial cells\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — pharmacological inhibition with activity assay and fractionation, single lab, no genetic confirmation\",\n      \"pmids\": [\"11467844\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Hydroxyurea induces rapid, transient phosphorylation of eNOS at Ser1177 in a PKA-dependent manner (partially via PKB/Akt), increases cAMP, cGMP, and intracellular Ca2+ in HUVECs, leading to increased NO production. This effect is blocked by competitive NOS inhibitors.\",\n      \"method\": \"Western blot for eNOS Ser1177 phosphorylation, PKA and Akt inhibitors, cAMP/cGMP measurement, intracellular Ca2+ imaging, NO measurement, NOS competitive inhibitors in HUVECs and TrHBMEC\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — pharmacological dissection of pathway with multiple readouts, single lab, no direct kinase reconstitution\",\n      \"pmids\": [\"16527893\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"FXR (farnesoid X receptor) activation induces eNOS expression in vascular endothelial cells at the transcriptional level. An imperfect inverted repeat DNA motif (IR2, -628 to -641 in rat eNOS promoter) acts as an FXR-responsive element. FXR ligand treatment increases eNOS mRNA, protein, and nitrite/nitrate production; the effect is blocked by actinomycin D.\",\n      \"method\": \"Actinomycin D transcription inhibition, eNOS promoter-reporter assay, pharmacological and genetic FXR activation, RT-PCR and Western blot for eNOS, nitrite/nitrate measurement\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — promoter functional analysis with multiple approaches, single lab\",\n      \"pmids\": [\"18006476\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PGC-1alpha promotes eNOS expression and activity through the orphan nuclear receptor ERRalpha. Endothelial-specific PGC-1alpha deletion sensitizes mice to endothelial dysfunction, while overexpression protects against it; protection is abolished by L-NAME or eNOS deletion, placing eNOS downstream of the PGC-1alpha/ERRalpha axis.\",\n      \"method\": \"Endothelial-specific PGC-1alpha knockout and transgenic mice, angiotensin-II hypertension model, L-NAME and eNOS KO epistasis, vascular reactivity assays\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis in vivo with multiple complementary mouse models, single lab\",\n      \"pmids\": [\"27910955\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"KLF2 increases eNOS phosphorylation at Ser1177 and eNOS dimerization, and activates the PI3K-Akt pathway and HSP90 to promote eNOS activity. Adenovirus-mediated endothelium-specific KLF2 overexpression enhances endothelium-dependent relaxation and flow-mediated dilation in diabetic mice.\",\n      \"method\": \"Adenoviral KLF2 overexpression in mouse aortic endothelium, RNA-sequencing, Western blot for eNOS phosphorylation and dimerization, Akt/HSP90 pathway analysis, vascular function assays in db/db mice\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo gene delivery with mechanistic pathway analysis, single lab\",\n      \"pmids\": [\"37347764\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Circulating NOS3 from blood cells (distinct from endothelial NOS3) ameliorates maladaptive left ventricular remodeling following reperfused myocardial infarction, reducing scar size and collagen deposition. Bone marrow chimeras devoid of blood-cell NOS3 show worsened LV remodeling compared to chimeras with both endothelial and blood-cell NOS3.\",\n      \"method\": \"Bone marrow transplantation chimera approach (NOS3-/- BM into WT mice), 60-min coronary occlusion/reperfusion model, serial echocardiography, pressure catheter hemodynamics, post-mortem histology\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — genetic chimera model with functional cardiac readout, single lab\",\n      \"pmids\": [\"25875863\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Functionally distinct platelet subpopulations exist: approximately 20% of platelets lack eNOS and consequently fail to produce NO and have downregulated sGC-PKG signaling. eNOS-negative platelets primarily initiate adhesion to collagen and form larger aggregates, while eNOS-positive platelets limit aggregate size via NO generation.\",\n      \"method\": \"Flow cytometry to separate eNOS-positive and eNOS-negative platelet subpopulations, flow chamber adhesion assays, aggregation experiments, MMP-2 secretion measurement, integrin αIIbβ3 activation assay\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — functional subpopulation separation with multiple readouts, single lab\",\n      \"pmids\": [\"29016749\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Hypoxia reduces eNOS mRNA in human endothelial cells by both decreasing transcription and reducing message stability (40-60% reduction). This leads to decreased NO production, as functional co-culture experiments show hypoxic endothelial cells stimulate significantly less cGMP production by smooth muscle cells.\",\n      \"method\": \"Northern blot, nuclear run-on transcription assay, mRNA stability assay, endothelial-smooth muscle co-culture cGMP measurement under normoxia and hypoxia\",\n      \"journal\": \"The American journal of physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — dual transcriptional and post-transcriptional mechanisms with functional co-culture validation, single lab\",\n      \"pmids\": [\"7526714\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TRPC5 channels activated by ATP-induced IP3 signaling stimulate eNOS/NOS activation and NO-cGMP-PKG signaling in neonatal rat cardiomyocytes. This TRPC5-eNOS axis negatively regulates hypertrophic TRPC3/6-calcineurin/NFAT signaling; pharmacological NOS inhibition potentiates ATP-induced NFAT activity and protein synthesis.\",\n      \"method\": \"NOS inhibitors, TRPC5 and TRPC6 selective pharmacological inhibition, NFAT reporter assay, NO measurement, PKG activity assay, protein synthesis measurement in NRCMs\",\n      \"journal\": \"Frontiers in pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — pharmacological pathway dissection with multiple readouts, single lab, no direct TRPC5-eNOS interaction assay\",\n      \"pmids\": [\"29872396\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"eNOS deficiency in mice causes podocyte cellular hypertrophy, mitochondrial abnormalities (increased number/decreased size), mitochondrial DNA mutations (d-17), reduced renal ATP and mitochondrial respiration. Conditioned medium lacking NO induces mitochondrial fragmentation in cultured podocytes, which is rescued by NO donor.\",\n      \"method\": \"eNOS knockout mice, ultrastructural analysis, mitochondrial respiration assay in primary podocytes, ATP measurement, NO donor rescue, endothelial conditioned medium experiments\",\n      \"journal\": \"Free radical biology & medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with ultrastructural, biochemical and cell culture rescue evidence, single lab\",\n      \"pmids\": [\"26119782\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"eNOS (NOS3) protects prostate cancer cells from TRAIL-induced apoptosis. Stable eNOS-expressing PC-3 clones are resistant to TRAIL-induced apoptosis, and NOS inhibition sensitizes LNCaP (high endogenous eNOS/Akt) cells to TRAIL. This protection is mediated downstream of Akt.\",\n      \"method\": \"Stable eNOS-overexpressing cell clone generation, NOS inhibitor treatment, apoptosis assays, Akt activity measurement in multiple prostate cancer cell lines\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — stable overexpression and pharmacological inhibition with defined apoptosis readout, single lab\",\n      \"pmids\": [\"15172122\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Adventitial expression of recombinant eNOS gene in fibroblasts (via adenoviral vector) restores NO production and bradykinin-induced relaxation in basilar arteries without endothelium, demonstrating that eNOS functional activity in adventitial fibroblasts is sufficient to regulate vascular tone through cGMP production. This effect is blocked by the NOS inhibitor L-NAME.\",\n      \"method\": \"Ex vivo adenoviral eNOS gene transfer to canine basilar arteries, endothelium-removal experiments, isometric tension recording, cGMP radioimmunoassay, electron microscopy for protein localization\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reconstitution via gene transfer in denuded vessels with functional and biochemical validation, single lab\",\n      \"pmids\": [\"9714129\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"NOS3/eNOS is a Ca2+/calmodulin-dependent oxygenase that produces NO from L-arginine in the endothelium; its activity is precisely tuned by multisite phosphorylation (activating at Ser1177, inhibitory at Thr495 via Rho-kinase or PKC), reversible post-translational modifications (S-glutathionylation and S-nitrosylation at defined cysteines that uncouple or inhibit the enzyme), protein-protein interactions (caveolin-1 tonically inhibits, HSP90/β-arrestin2/GIT1 stimulate), and subcellular compartmentalization between the plasma membrane (primary activity site, ~10-fold more active) and trans-Golgi network (required for Golgi structural integrity); BH4 cofactor availability determines coupling state, and upstream kinases including Akt, PKCalpha, AMPK, and ERK5 (regulated by PKCζ) converge on eNOS phosphorylation to control NO output, while eNOS-derived NO itself drives a negative feedback through Src-mediated caveolin-1 phosphorylation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"NOS3 (eNOS) is a Ca2+/calmodulin-regulated enzyme that generates nitric oxide (NO) to control vascular tone, endothelial barrier function, and broader cardiometabolic homeostasis, with its output tuned by multisite phosphorylation, redox-based cysteine modifications, protein partners, and subcellular compartmentalization [#8, #14]. Enzyme activity is bidirectionally set by phosphorylation: activating phosphorylation at Ser1177 is driven by PKCalpha, AMPK, PKA/Akt, and KLF2-linked PI3K-Akt/HSP90 signaling, whereas inhibitory Thr495 phosphorylation by Rho-kinase or PKC suppresses NO production [#4, #10, #1, #6, #30]. Phosphorylation status alone, however, does not predict NO output, establishing activation as a multi-input process rather than a single switch [#14]. Catalytic coupling depends on redox state and cofactor availability: S-glutathionylation of reductase-domain cysteines and BH4 deficiency uncouple the enzyme to produce superoxide or peroxynitrite, while iNOS-dependent S-nitrosylation at Cys94/Cys99 redirects eNOS into a beta-catenin transcriptional complex [#0, #25, #22]. eNOS is held inactive by caveolin-1 and is reciprocally regulated by its own product through an NO-Src-caveolin-1 Tyr14 negative-feedback loop, while beta-arrestin2/GIT1 complexes and HSP90 stimulate activity; HSP90 association and eNOS protein stability are themselves controlled by chaperone and degradation pathways (Nox4/ER stress, TXNDC5-HSF1-HSP90) [#2, #3, #13, #15, #23]. Spatially, endogenous eNOS partitions between the plasma membrane, where it is ~10-fold more active, and the trans-Golgi network, where its activity is required for Golgi structural integrity [#8]. Beyond the vasculature, eNOS-derived NO S-nitrosylates and activates wild-type Ras to support tumor maintenance, governs Ser1177-dependent insulin sensitivity, and is required for hepatocyte mitochondrial fatty acid oxidation [#9, #16, #24].\"\n,\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Established that eNOS NO output is gated at the level of message abundance, showing oxygen tension controls endothelial NO production through transcription and mRNA stability.\",\n      \"evidence\": \"Nuclear run-on, mRNA stability assays, and endothelial-smooth muscle co-culture cGMP measurement under hypoxia\",\n      \"pmids\": [\"7526714\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Promoter elements and trans-factors not identified\", \"Does not address post-translational regulation\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Demonstrated cell-type-specific transcriptional downregulation of NOS3 by cAMP in cardiomyocytes, linking eNOS abundance to beta-adrenergic and muscarinic contractile responses.\",\n      \"evidence\": \"cAMP-elevating drugs in vitro and milrinone in vivo with cardiomyocyte contractility assays\",\n      \"pmids\": [\"8621775\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Transcription factor mediating cAMP effect not identified\", \"Restricted to cardiomyocyte context\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Showed eNOS catalytic function is sufficient to control vascular tone independent of its native endothelial location, by reconstituting NO-dependent relaxation in denuded vessels via adventitial fibroblast expression.\",\n      \"evidence\": \"Ex vivo adenoviral eNOS gene transfer to endothelium-removed canine basilar arteries with tension recording and cGMP RIA\",\n      \"pmids\": [\"9714129\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not test physiological regulation of ectopic enzyme\", \"cGMP-independent effects not addressed\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Connected receptor signaling to eNOS by showing PI3K mediates beta2-adrenergic and IGF-1 activation of eNOS and its partitioning into membrane rafts.\",\n      \"evidence\": \"PI3K activity and citrulline assays with Wortmannin inhibition and Triton X-100 fractionation in rat aortic endothelial cells\",\n      \"pmids\": [\"11467844\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Pharmacological inhibition only, no genetic confirmation\", \"Direct kinase target on eNOS not defined here\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Distinguished the temporal role of eNOS-derived NO in barrier control, showing NO mediates only the acute phase of TNF-induced endothelial permeability.\",\n      \"evidence\": \"ecNOS antisense knockdown with albumin permeability assay and NO donor rescue in pulmonary microvessel monolayers\",\n      \"pmids\": [\"11290515\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Antisense specificity limited\", \"Mechanism of NO-independent late-phase dysfunction unresolved\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Resolved isoform-specific activating kinase input by showing PKCalpha drives Ser1177 phosphorylation and NO production with in vivo blood-flow consequences.\",\n      \"evidence\": \"PKCalpha overexpression/siRNA, dominant-negative mutant, and in vivo adenoviral transfer with L-NAME control\",\n      \"pmids\": [\"16081872\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PKCalpha acts directly or via intermediate kinase not fully resolved\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Linked hyperhomocysteinemia to eNOS dysfunction via PKC-driven inhibitory Thr495 phosphorylation and reduced expression.\",\n      \"evidence\": \"CBS-/- mice, aortic ring assays, and PKC inhibitor rescue in human aortic endothelial cells\",\n      \"pmids\": [\"16210565\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific PKC isoform not identified\", \"Mechanism of expression decrease not defined\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identified a post-transcriptional mechanism by which laminar shear stress stabilizes eNOS mRNA through poly(A) tail lengthening and enhanced translation.\",\n      \"evidence\": \"Poly(A) tail analysis, actinomycin D chase, and polysome fractionation in sheared endothelial cells\",\n      \"pmids\": [\"15905462\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Polyadenylation machinery responsible not identified\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identified NOSIP as a direct eNOS-interacting protein co-localizing in airway and vascular tissues.\",\n      \"evidence\": \"Co-immunoprecipitation from lung tissue with immunohistochemistry\",\n      \"pmids\": [\"15684328\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single Co-IP without functional activity assay\", \"Effect on eNOS activity not directly demonstrated\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Defined AMPK as a distinct Ser1177-activating kinase under fenofibrate stimulation, independent of PKA/PI3K.\",\n      \"evidence\": \"Phospho-Western blots and pharmacological inhibitor dissection in HUVECs\",\n      \"pmids\": [\"16442496\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No direct AMPK-eNOS reconstitution\", \"Single method per endpoint\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Mapped a PKCzeta-ERK5 axis controlling eNOS protein stability, showing TNFalpha lowers eNOS via PKCzeta phosphorylation of ERK5 at S486.\",\n      \"evidence\": \"Co-IP, mammalian 2-hybrid, in vitro kinase assay, and ERK5 phosphomutant analysis\",\n      \"pmids\": [\"20538799\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which ERK5 stabilizes eNOS not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Established BH4 cofactor deficiency as the mechanism of diabetic eNOS uncoupling, where eNOS produces peroxynitrite and BH4/sepiapterin repletion re-couples the enzyme.\",\n      \"evidence\": \"eNOS transgenic/adenoviral overexpression in db/db mice with hepatic I/R injury and BH4 rescue\",\n      \"pmids\": [\"16763164\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative BH4 thresholds for coupling not defined\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Showed eNOS subcellular destination is agonist-selective, with ACh routing to the trans-Golgi (vasodilation) and PAF to cytosol (hyperpermeability).\",\n      \"evidence\": \"eNOS-GFP imaging, lipid raft analysis, and permeability assays in ECV-304 cells\",\n      \"pmids\": [\"16679407\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No mutagenesis defining the trafficking signal\", \"Endogenous protein not examined\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Connected hydroxyurea pharmacology to eNOS, showing PKA-dependent (partly Akt) Ser1177 phosphorylation and NO production.\",\n      \"evidence\": \"Phospho-Western, kinase inhibitors, cyclic nucleotide and Ca2+ measurement in HUVECs\",\n      \"pmids\": [\"16527893\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No direct kinase reconstitution\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identified Rho-kinase as the direct kinase for inhibitory Thr495 phosphorylation, linking RhoA signaling to NO suppression.\",\n      \"evidence\": \"In vitro kinase assay with constitutively active Rho-kinase plus Y27632 inhibition in HUVECs\",\n      \"pmids\": [\"17651694\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological agonists engaging this axis only partly defined\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identified FXR as a transcriptional activator of eNOS via a defined promoter response element.\",\n      \"evidence\": \"Promoter-reporter assays, actinomycin D, and FXR ligand treatment in endothelial cells\",\n      \"pmids\": [\"18006476\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Element characterized in rat promoter; human conservation not shown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Revealed a non-vascular oncogenic function, showing AKT-activated eNOS S-nitrosylates and activates wild-type Ras to drive tumor initiation and maintenance.\",\n      \"evidence\": \"Genetic/pharmacological eNOS phospho-blockade, Ras S-nitrosylation assays, and mouse tumor models with epistasis\",\n      \"pmids\": [\"18344980\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cysteine target on Ras not mapped here\", \"Tissue specificity of the axis not fully defined\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Defined reversible S-glutathionylation of reductase-domain cysteines as a redox switch that uncouples eNOS toward superoxide and is elevated in hypertension.\",\n      \"evidence\": \"In vitro reconstitution with cysteine mutagenesis, EPR, and hypertensive vessel analysis\",\n      \"pmids\": [\"21179168\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Enzymes mediating de/re-glutathionylation in vivo not identified\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Placed Nos3 in a developmental cell-survival pathway, showing it acts downstream of Tbx5 to drive endocardial apoptosis and atrial septal defects.\",\n      \"evidence\": \"Conditional Tbx5 knockout and compound Tbx5/Nos3 haploinsufficiency with apoptosis assays and echocardiography\",\n      \"pmids\": [\"20974940\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which Tbx5 represses Nos3 not defined\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Established a product-driven negative feedback loop in which eNOS-derived NO activates Src to phosphorylate caveolin-1 Tyr14, enhancing inhibitory eNOS/Cav-1 binding.\",\n      \"evidence\": \"FRET biosensors, Co-IP, eNOS siRNA, and Cav-1 phosphomimetic/phosphodefective mutants\",\n      \"pmids\": [\"22323292\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative contribution to steady-state NO not defined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstrated that Ser1177 phosphorylation is a physiological setpoint for systemic metabolism using phosphomutant knockin mice.\",\n      \"evidence\": \"S1176A and S1176D knockin mice with metabolic phenotyping and high-fat diet challenge\",\n      \"pmids\": [\"23291238\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue source of the metabolic NO effect not isolated\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified a blood-cell pool of NOS3 distinct from endothelium that limits maladaptive cardiac remodeling after myocardial infarction.\",\n      \"evidence\": \"Bone marrow chimera transplantation with reperfused MI model and serial echocardiography\",\n      \"pmids\": [\"25875863\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Blood cell type responsible not pinpointed\", \"Single lab\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Linked endothelial eNOS-derived NO to podocyte mitochondrial integrity, showing eNOS loss causes mitochondrial abnormalities rescuable by NO donor.\",\n      \"evidence\": \"eNOS knockout mice with podocyte ultrastructure, respiration assays, and conditioned-medium NO rescue\",\n      \"pmids\": [\"26119782\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular target of NO in podocyte mitochondria not defined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Placed eNOS downstream of the PGC-1alpha/ERRalpha axis as the effector protecting against endothelial dysfunction.\",\n      \"evidence\": \"Endothelial PGC-1alpha knockout/transgenic mice with L-NAME and eNOS-KO epistasis\",\n      \"pmids\": [\"27910955\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct ERRalpha binding to eNOS promoter not shown here\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Connected oxidative aging to eNOS uncoupling via Nox4-driven ER stress that dissociates HSP90 from eNOS.\",\n      \"evidence\": \"Serial-passage HUVEC aging, Nox4 siRNA, ER stress inhibitors, and HSP90-eNOS Co-IP\",\n      \"pmids\": [\"28916474\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural or reconstitution data on HSP90-eNOS dissociation\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Revealed platelet heterogeneity in which an eNOS-negative subpopulation drives adhesion while eNOS-positive platelets limit aggregate size.\",\n      \"evidence\": \"Flow-cytometric subpopulation separation with adhesion and aggregation assays\",\n      \"pmids\": [\"29016749\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Basis of eNOS expression dichotomy not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Clarified caveolin-1 as both a stabilizer and inhibitor of eNOS, with eNOS activity in turn destabilizing Cav-1 oligomers to drive caveolar endocytosis.\",\n      \"evidence\": \"Reciprocal Cav-1 siRNA/overexpression, S-nitrosylation assay, and endocytosis measurement\",\n      \"pmids\": [\"29563255\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry balancing stabilization versus inhibition not resolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined site-specific S-nitrosylation at Cys94/Cys99 that redirects eNOS into a beta-catenin transcriptional complex promoting endothelial activation.\",\n      \"evidence\": \"Cys mutagenesis, S-nitrosylation assay, eNOS/beta-catenin Co-IP, and reporter assays\",\n      \"pmids\": [\"29471036\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Source iNOS context required; endogenous relevance partly defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Established TRPC5 as an upstream activator of eNOS that restrains hypertrophic TRPC3/6-calcineurin/NFAT signaling in cardiomyocytes.\",\n      \"evidence\": \"TRPC5/6 inhibitors, NFAT reporter, PKG activity, and protein synthesis assays in NRCMs\",\n      \"pmids\": [\"29872396\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No direct TRPC5-eNOS interaction assay\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Mapped endogenous eNOS to two pools with distinct activity, showing plasma-membrane eNOS is ~10-fold more active while Golgi eNOS activity maintains Golgi structure.\",\n      \"evidence\": \"Subcellular-targeted DNA fluorescent NO probe (NOckout) with quantitative live-cell mapping\",\n      \"pmids\": [\"32152543\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism coupling Golgi NO to structural maintenance not defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified a beta-arrestin2/GIT1/eNOS stimulatory complex required for sinusoidal endothelial NO production that is lost in liver injury.\",\n      \"evidence\": \"Reciprocal Co-IP, beta-Arr2 knockout mice with bile duct ligation, and rescue with kinase inhibition\",\n      \"pmids\": [\"32404425\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural organization of the tripartite complex not resolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Refuted phosphorylation as a reliable surrogate for NO output, showing insulin/VEGF cause eNOS phosphorylation without NO while histamine/ATP cause both.\",\n      \"evidence\": \"Multispectral NO/Ca2+ biosensor imaging with chemogenetic activation and phospho-immunoblot\",\n      \"pmids\": [\"31527268\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Additional activation steps distinguishing the two responses not fully defined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstrated a hepatocyte-intrinsic eNOS requirement for mitochondrial fatty acid oxidation and mitophagy, protective against diet-induced NASH.\",\n      \"evidence\": \"Hepatocyte-specific eNOS deletion and AAV knockdown/overexpression with mitochondrial respiration and mitophagy readouts\",\n      \"pmids\": [\"34380696\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct mitochondrial NO targets in hepatocytes not identified\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined a BACE1-occludin-caveolin-1 pathway in which BACE1 elevation increases membrane caveolin-1 to sequester and inhibit eNOS in hypertensive microvessels.\",\n      \"evidence\": \"MS substrate identification, BACE1 transgenic mice, inhibitor experiments, and human hypertensive microvessels\",\n      \"pmids\": [\"35382554\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Link between occludin cleavage and Cav-1 accumulation mechanistically incomplete\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established a TXNDC5-HSF1-HSP90 degradation axis controlling eNOS protein levels and validated CRISPR targeting to restore eNOS and reduce atherosclerosis.\",\n      \"evidence\": \"Endothelium-specific Txndc5 knockout in ApoE-/- mice, nanoparticle CRISPR delivery, and proteasome/stability assays\",\n      \"pmids\": [\"35061532\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether HSP90 reduction alone fully accounts for eNOS loss not resolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined a VEGFR2-Y1173/PLCgamma-Ca2+/PKC-eNOS pathway in which NO nitrates and activates Src to disrupt VE-cadherin junctions and cause vascular leakage.\",\n      \"evidence\": \"Vegfr2 Y1173F knockin and endothelial Plcg1 knockout mice with Src/VE-cadherin and permeability readouts\",\n      \"pmids\": [\"37651195\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relationship to the eNOS phosphorylation switches not integrated\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified KLF2 as a transcriptional/signaling node enhancing eNOS Ser1177 phosphorylation, dimerization, and PI3K-Akt/HSP90 activity to improve diabetic vascular function.\",\n      \"evidence\": \"Adenoviral endothelial KLF2 overexpression with RNA-seq, phospho/dimerization Western, and vascular function in db/db mice\",\n      \"pmids\": [\"37347764\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct versus indirect effect of KLF2 on eNOS dimerization not separated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the converging phosphorylation, redox, cofactor, partner, and compartmentalization inputs are integrated quantitatively to determine actual NO output in vivo remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No unified model relating phospho-state, coupling, and localization to measured NO\", \"Structural basis of partner-driven activation/inhibition undefined\", \"Tissue-specific eNOS pools incompletely mapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [0, 25, 8]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [9, 22]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [34, 2]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [8, 26, 5]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [8, 5]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [4, 1, 21]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [16, 24, 25]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [23, 20, 6]},\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [32]}\n    ],\n    \"complexes\": [\n      \"beta-arrestin2/GIT1/eNOS complex\",\n      \"eNOS/caveolin-1 complex\",\n      \"HSP90/eNOS complex\"\n    ],\n    \"partners\": [\n      \"CAV1\",\n      \"HSP90AA1\",\n      \"ARRB2\",\n      \"GIT1\",\n      \"SRC\",\n      \"NOSIP\",\n      \"CTNNB1\",\n      \"ROCK1\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}